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1. GENERAL INTRODUCTION 
 
 
Medicinal Chemistry is a Science Which includes all branches of Chemistry and 
biology. The discipline of Medicinal chemistry is devoted to the discovery and development 
of new agents for treating diseases. 
Most of this activity is directed to new natural or synthetic organic compounds. 
Inorganic compounds continue to be important in therapy,  
Eg: Trace elements in nutritional therapy, antacids and radiopharmaceuticals but 
organic compounds with increasingly specific pharmacological activities are clearly 
dominant. 
The structures of biologically molecules usually contains more than one type of 
functional group. This means that the properties of these molecule are a mixture of those of 
each of the functional group present plus properties characteristic of the compound. 
Pharmaceutical chemistry  is a branch of science that makes use of the general law of 
chemistry to study drugs in respect to their synthesis, composition, physical and chemical 
properties, their use of treating disease. 
Once a new pharmaceutical lead compound has been found out , extensive efforts are 
put in to make series of analogue with better activity. 
Nowadays Medicinal chemistry involved in molecular design and molecular docking 
for better biological activity with less toxic effects. 
Medicinal chemistry remains a challenging field which involves invention of new 
drugs to treat emerging diseases. 
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1.1 CHALCONES57 
 
Flavonoids comprise a large family of plant derived poly phenolic compounds 
classified as anthocyanidins, flavonols, chalcones, flavones, isoflavones. Chalcones an 
important intermediate of flavonoid synthetic pathway, has been shown to exhibit diverse 
biological and pharmacological activities. 
Chalcones are unsaturated ketone containing the reactive keto ethylenic group -CO 
CH=CH. These are coloured compounds because of the presence of chromophore. 
Chalcones are also called as benzalacetophenone or benzylidine acetophenone or 
phenyl styryl ketone. 
                
                                   
                         
                                     1,3 - Diphenyl - 2 - Propane- 1- one. 
Different methods are available for the preparation of chalcones. The most convenient 
method is the claisen-schmidt condensation of equimolar quantities of aryl methylketone and 
aryl aldehyde.   
This reaction is catalyzed by acids and bases under homogenous or heterogenous 
conditions.  
Chalcone derivative have wide variety of biological activities reported for these 
compounds include anti-inflammatory, anti-fungal, antibacterial, antimalarial and antitumor 
activity. 
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Chalcones with antioxidant activity (and compounds with such activity in general) 
have been demonstrated to have anticancer, anti cardiovascular, anti inflammatory and many 
other activities. 
Claisen-schmidt Reaction: 
This is the most convenient method for synthesis of chalcones. in this reaction 
equimolar quantities of substituted accetophenone condensed with substituted aldehydes in 
the presence of aqueous alcoholic alkali. 
The condensation of aromatic aldehydes having no -hydrogen, with aliphatic 
aldehydes, ketones or esters, having active hydrogen, in the presence of 10% alkali solution 
to give - unsaturated aldehydes or ketones is known as claisen schmidt reaction. 
 
                               
 
 
 
 
Various condensing agents used in synthesis of chalcones: 
Alkali: 
 It is most used condensing agents for synthesis of chalcones. It is used as an Aqueous 
solution of suitable concentraton 30%, 40%, 50%, 70%. 
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Hydrochloric acid: 
dry hydrochloric acid gas in a suitable solvent like ethylacetate at 0◦C was used as a 
condensing agent in a few synthesis of chalcone from aromatic ketones. 
Other condensing agents: 
1. Amino acid 
2. Perchloric acid 
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1.2 PYRAZOLINE58 
Among nitrogen containing five membered heterocycles, pyrazolines have proved to 
be the most useful framework for biological activities. The pharmaceutical importance of 
these compounds lies in the fact that they can be effectively utilized as antibacterial, 
antifungal, antiviral, antiparasitic, antitubercular and insecticidal agents. In 1967 Jarboe, 
reviewed the chemistry of pyrazolines,which have been studied extensively for their 
biodynamic behavior and industrial applications.  
                                                         
N
N
H  
Synthetic aspects: 
Different methods for the preparation of 2-pyrazoline derivatives documented in 
literature are as follows.  
1. The most common procedure for the synthesis of 2-pyrazolines is the reaction of an 
aliphatic or aromatic hydrazine with α,β-unsaturated carbonyl compounds. 
2. 2-Pyrazolines synthesized by the cycloaddition of diazomethane with substituted 
chalcones.    
3. 2-Pyrazolines can also be prepared by the condensation of chalcone dibromidewith 
hydrazine.  
4. Epoxidation of chalcones i.e. epoxy ketones which reacted with hydrazine and phenyl 
hydrazine to give pyrazolines.  
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5. A number of diarylidene cycloalkanones on reaction with hydrazine hydrate produce 
pyrazolines.  
6. Dipolar cyclo addition of nitrilimines to dimethyl fumarate, fumaro nitrile and the N-aryl 
maleimides yields the corresponding pyrazolines.  
7. Reaction of Et 2-(phenylazo)-3-oxobutanoates with nicotinic acid hydrazide using glacial 
acetic acid gives following type of pyrazoline derivatives.   
Therapeutic importance: 
 Pyrazole belongs to the family of azoles i.e. five-membered ring containing nitrogen 
and carbon atom. Considerable attention has been focused on pyrazolines and substituted 
pyrazolines due to their interesting biological activities. The dihydro pyrazoles are called 
pyrazolines. Some substituted pyrazolines and their derivatives have been reported to possess 
some interesting biological activities such as anticancer, insecticidal, antibacterial etc. They 
have found to possess antifungal, antidepressant, anticonvulsant, anti-inflammatory, 
antibacterial and anti- tumor  properties. 
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1.3- 3,4 DIHYDROPYRIMIDINE59 
 
Pyrimidine is a six membered hetero cyclic ring having two nitrogen atoms in their 
ring. Dihydropyrimidine are the compounds which are obtained by cyclocondensation 
reaction which having different products. The dihydropyrimidine synthetic products has 
different medicinal uses such as Antihypertesive, Antibacterial, Antifungal, ad Anti-oxidant 
property. 
                            
NHNH
O
3,4-dihydropyrimidin-2(1H)-one
 
Biolgical imporatance: 
In medicinal chemistry Pyrimidine derivatives have been very well known for their 
therapeutic applications. The presence of pyrimidine base in thymine, cytosine and uracil, 
which are the essential building blocks of nucleic acids, DNA and RNA is one of the possible 
reason for their activities. Vitamins are essential for the body. Pyrimidine ring is found in 
vitamins similar to riboflavin, thiamine and folic acid. 
Preparation of 3,4-dihydropyrimidine from chalcone: 
A mixture of equimolar quantities of chalcone and urea were dissolved in 25ml of 
ethanol and 5ml of potassium hydroxide and refluxed on water bath for 8hr. the solvent was 
evaporated and the precipitation was recrystallized from ethanol. 
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1.4 - ANTI-OXIDANT61 
 
An anti-oxidant is a molecules that inhibits the oxidation of other molecules. 
Oxidation is a chemical reaction that transfer electrons or hydrogen from a substance to an 
oxidizing agent. 
Oxidation reaction can produce free radicals. In turn, these radicals can start chain 
reaction. When the reaction occurs in a cell, it can cause damage or death to the cell. Anti-
oxidants terminate these chain reaction  by remove free radical intermediates, and inhibit 
other oxidation reaction. So anti-oxidants are often reducing agents such as thiols, ascorbic 
acid or polyphenols. 
Mechanism of Anti-oxidant: 
LMWAs (Low Molecularr Weight antioxidants) are small molecules that have 
frequently infiltrate cells, accumulate (at high concentrations) in specific compartments 
associated with oxidative damage, and then are regenerated by the cell. 
In human tissues, cellular LMWAs are obtained from various sources. Glutathione, 
nicotinamide, adenine dinucleotide and carosins are synthesized by the cells. Uric acid and 
billirubin are waste products of cellular metabolism. Ascorbic acid, tocopherols and 
poyphenols are anti-oxidants obtained from the diet.      
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Conditions Associated with oxidative damage: 
 Ageing 
 Atherosclerosis 
 Cancer 
 Cataracts 
 Diabetes 
 Arthritis and inflammatory disease 
 Pulmonary infaction 
 Pancreatitis 
 Ischemia 
 Skin lesions 
 Parkinson’s disease 
 Renal damage. 
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1.5  INFLAMMATION60 
The word comes from the latin “inflammo”, meaning “ I set alight, I ignite” is a 
complex biological response of vascular tissues to harmful stimuli, including pathogens, 
damaged cells or irritants. The classical signs of acute inflammation are pain, heat, redness, 
swelling and loss of function. Inflammation is a defence mechanism of the body to remove 
the injurious stimuli and to initiate the healing process. 
Inflammation can be classified as acute or chronic. Acute inflammation is the initial 
response of the body to harmful stimuli and is achieved by the increased movement of plasma 
and leukocytes(granulocytes) from the blood into the injured tissues. Prolonged inflammation 
known as chronc inflammation is a dangerous, out of control immunological reaction. 
Acute inflammation: 
Causative Agent -   Bacterial pathogens, injured tissues. 
Major cell involved -  Neutrophils, basophils, eosinophils, mononuclear cells (monocyte,  
  Macrophage) 
Onset    -  Immediate. 
Duration  -  Few  days. 
Out comes   -  Resolution, abcess formation, chronic inflammation. 
Chronic inflammation:  
Causative agent  -  Non-degradable pathogens, viral infection, persistant foreign  
Bodies or autoimmune reactions. 
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Major cells   -  Mononuclear cells, (monocytes, macrophages, lymphocytes,  
       Plasma cells ), Fibroblasts. 
Onset    -  Delayed. 
Duration    - Upto many months or years. 
Outcomes   - Tissue destruction, fibrosis, necrosis. 
Causes of inflammation: 
 The main causes of inflammation are burn, chemical irritants, toxins, ionizing 
radiations, stress, trauma and alcohol. 
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Mechanism of inflammation: 
 The mechanism of inflammatory  pathway is classified as follows : 
 Arachidonic acid (AA) dependent pathway which includes Cyclo oxygnase(COX), 
Lipoxygenase(LOX) and Phospholipase A2 (PlA2) as mediators. 
 AA – indendent pathway which include nitric oxide synthase(NOS), Peroxisome, 
Proliferator activated receptor(PPAR) and NSAID activated gene – 1(NAG  - 1). 
Mediators of inflammation: 
 The mediators of inflammation are histamine, bradySkinins, prostoglandins, 
thrombaxane A2, prostacyclin, leukotrienes, platelet activating factor and interleukin-1. 
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1.6 - DIABETES MELLITUS60 
Diabetes mellitus is a disorder of carbohydrate, fat, protein metabolism. A defective 
or deficient insulin secretory response, which translates into impaired glucose use is a 
characteristic feature of Diabetes mellitus.  
Classification and incidence: 
Diabetes Mellitus represents a group of disorder that have hyperglycemia as a 
common feature. it may arise secondarily from any disease causing extensive destruction of 
pancreatic islets, such as pancreatitis, tumors, certain drugs, iron overload 
(Hemochromatosis). 
The most common and important forms of diabetes mellitus arise from primary 
disorders of the islet cell insulin system. 
Types of Diabetes Mellitus: 
 Primary (idiopathic) 
Type-I (Insulin dependent Diabetes mellitus) 
Type-II(Non-insulin dependent Diabetes Mellitus) 
Secondary 
Chronic Pancreatitis. 
Hormonal Tumors (eg. Pheochromocytoma).    
Type-I DM is also called as Juvenile Diabetes. 
Type-II DM is also called as Adult-onset diabetes. 
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Pathogenesis of Type I DM: 
This form of Diabetes results from a severe, absolute lack of insulin caused by a 
reduction in the beta cell mass. Type-I diabetes usually developed in childhood, becoming 
manifest and severe at puberty. without insulin they develope serious metabolic 
complications such as acetic keto acidosis and coma. 
The interlocking mechanism are resposible for the islet cell destruction. 
1.Genetic susceptiblity 
2.Autoimmunity 
3.Environmental insult 
 Pathogenesis of type II DM: 
This type of DM is commonly seen in more than 30 years old. The metabolic defects 
that characterize type-II Diabetes are a dearrangement in Beta cell secretion of insulin and an 
inability of peripheral tissues to respond to insulin. 
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1.7 - TUBERCULOSIS40 
 Tuberculosis is a chronic disease and a major health problem in developing countries. 
About 1/3rd of the wolrd population is infected with Mycobacterium tuberculosis. As per 
WHO estimate, 9 million people globally develop active TB  and 1.7 million die of it 
annually. In india , it is estimated that nearly 2 million people develop active disease every 
year and about 0.5 million 
 
TB Invades/Infects the Lung
Effective immune
response
Infection limited 
to small area of lung
Immune response
insufficient
 
 
 Common symptoms 
 Cough (2-3 weeks or more) 
 Coughing Up blood 
 Chest pain 
 Fever 
 Night sweat 
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 Feeling week and tired 
 Losing weight 
 No appetite 
Treatment for tuberculosis: 
 Most TB is Curable but four or more drugs required for the simplest 
regimen. 
 6-9 or more months of treatment required. 
 Person must be isolated until non-infectious. 
 Directly observed therapy to assure adherence/completion recommended 
 Side effects and toxicity common. 
 Other medical and Psycho social conditions for complicate therapy when 
TB may be severe and drug-drug interaction common. 
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6. Nielson et al., investigated the antibacterial activity of hydroxy chalcones, 2004. 
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their anticancer activity against three human cancer cell lines, 2010.                
                                    
11. Parekh et al., synthesized a series of benzofuran 2-yl (4,5-dihydro -3,5- 
substituted diphenyl pyrazol-1-yl) methanone derivatives with anticancer activity, 2011. 
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12. Liu et al., reported on N-methyl piperidinyl chalcones with anticancer 
activity,2006. 
                                                     
                              
13. Parekh et al., synthesized indolyl chalcones derivatives with anticancer activity. 
For their anti proliferative activity and reversal of multi drug resistance on human MDR1- 
gene transferred mouse lymphoma cells, 2011.  
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15. Rao et al., reported a series of twenty three  3', 4', 5' – trimethoxy chalcones 
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16. Sayed et al., reported a series of sulfonamide derivatives of (1,3,4) thiadiazolo 
(3,2) pyrimidine were formed and investigated as antitumor agents. Some of the newly 
prepared compounds were tested for their invitro and invivo antitumor activities, 2011. 
                                   
17. Reddy et al., synthesized a series of novel  bichalcone analogues and evaluated in 
lipopolysaccharide activated microglial cells as inhibitors of nitirc oxide and for invitro 
anticancer activity  using a limited panel of four human cell lines, 2010. 
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 18. Susanne et al., synthesized a series of 2'-hydroxy chalcones and their oxidative 
cyclization products for their antioxidant and lipoxygenase inhibitory activity. 
 
                                                  
 19. Via et al., synthesized and evaluate the conjucates of α,β- unsaturated ketone 
systems phenyl butanone and diaryl propanone with the tricyclic planar pyrroloquinoline 
nucleus, 2008.  
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  20. Seo et al., synthesized the chalcones a new clss of glycoside inhibitors. Non amino 
chalcones had no inhibitory activity. However amino chalcones had strong glycosidase 
(α,glucosidase, α, amylase and β, amylase) inhibitory activities, 2005. 
                               
 21. Eric et al., studied a targeted series of chalcone and dienone hybrid compounds 
containing aminoquinoline and nucleoside templates was synthesized and evaluated for in 
vitro antimalarial activity,2010. 
                                  
 22. Acharya et al., were synthesized a series of 1,3,5 tri substituted pyrazoline and 
evaluated in vitro antimalarial efficacy against chloroquine sensitive as well as chloroquine 
resistant strains of plasmodium falciparum, 2010. 
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 23. Said et al., synthesized a series of diazepine, pyrimidine, fused triazolo pyrimidine 
and imide derivatives with analgesic activity, 2009. 
                         
 24. Thanh-Dao Tran et al., discoverd some heterocyclic chalcone analogues such as 
Pyridine 2-yl chalcones, Furan 2-yl chalcones, and Thiophene 2-yl chalcones and screened 
for their antibacterial activity, 2012. 
 
                                                 
                           
 
 25. Nimavat and Joshi et al., synthesized 2-amino-4-(3-bromo phenyl)-6-aryl-
Pyrimidine from chalcone on treatment with guanidine hydrochloride and screened for their 
antitubercular activity,2013.          
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 26. Setharaman venkatraman et al., synthesized some novel Pyrazolines from 
chalcones and evaluated for antibacterial and anti inflammatory. 
                                               
               R1=H, 4-OCH3, 4-CH3, 4-OH 
               R2= 2-0H, H  
              R3= 4-NO2, 4-OCH3, 4-Cl, 4-NO2.  
 27. Ashvin D. Panchal et al., synthesized triazole linked chalcone derivatives as 
antibacterial and antifungals. 
                                
         28. Sahoo Biswa Mohan et al., carried out the synthesis of Benzimidazolyl chalcones 
derivatives, 2010. 
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 29. S.Mhan et al., synthesized some chloro, methoxy substituted chalcone derivatives 
and tested for anti microbial activity, 2012. 
                                           
 
 
 
 
       30. Gayathri Banda et al., synthesized fluoro, chloro 2- substituted Benzimidazole 
thiazine derivatives and evaluated for Antibacterial and Analgesic activities, 2012. 
                                           
 31. Kalirajan et al., reported on synthesis and biological evaluation of some 
heterocyclic derivatives of chalcones, 2009. 
                                          
 32. P.Prasanna Raja et al., reported the synthesis and biological evaluation of some 
chalcone derivatives as esters, 2010.   
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 33. Devaux, Nuhrich et al., discovered some nitrofuryl  chalcones as Antibacterials, 
1978. 
                                            
 34. Dandia et al., prepared chalcones having indole moiety and studied for 
Antibacterial and Anti fungal activities, 1993.  
                                           
 35. Javad Safaei Ghomi et al., reported on synthesis of Pyrimidine 2-ones under 
ultrasound irradiation from chalcones, 2010. 
                                                     
 36. M.V.Jyothi et al., synthesized some novel chalcones of 3-acetyl pyridine and their 
Pyrimidine derivatives and screened for antimicrobial activity, 2012. 
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 37. Kapubalu et al., synthesized a series of novel isoxazole derivatives via chalcone 
derivatives and evaluate with their bioogical activity, 2011. 
                                        
 38. Mustafa et al., studied a targeted series of noval chalcone derivatives containing 
4,7-ethano-isoxazole-1,3-dione with antibacterial activity, 2013. 
                                          
                           R1-OH.,  R2- OH 
 39. Tribbhuvan singh et al., reported on synthesized novel Aryl and hetero Aryl 
chalcone analogues with Anti inflammatory and Antibacterial activity, 2012. 
                                                                               
  40. Rajashri et al., synthesized on study of novel chalcone derivatives and Evaluate 
their antimicrobial activity, 2012. 
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  41. Varun arora et al., reported on synthesis and evaluation of chalcone derivatives of 
2-acetyl napthalene with antifungal and antibacterial activity, 2012. 
                                              
 42. Yerra Koteswara Rao et al., synthesized 2-oxygenated chalcone derivatives with 
anticancer activity, 2004. 
                                            O
OCH3H3CO
OCH3  
 43. SD.Tala et al., reported on synthesis of some new chalcone and pyrazole 
derivatives with antimicrobial activity, 2013. 
                                        
N N
H3CO
CH3 CH3
CH2
CH3   
 44. Seranthimata samshudin et al., synthesized functionalized derivatives of versatile 
synthon 4,4-dihydro chalcones derivatives with antimicrobial activity, 2012. 
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N
N
F
F  
  45. Y.Rajendra Prasad et al., reported QSAR studies on chalcone derivatives as 
Antibacterial agent against Bacillus pumilis, 2008. 
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3. AIM OF STUDY 
              In the present study I have decided synthesis of two nucleus from chalcone 
derivatives.  One is N-phenylpyrazoline and the other one is 3,4-dihydropyrimidine  
The N-phenyl Pyrazoline ring with aryl substitution at third and fifth position exhibits 
better biological activities. 
The 3,4 dihydropyrimidine with aryl substitution at fourth and sixth position exhibits 
better biological activities. 
 N-phenyl Pyrazoline with phenyl substitution at third position and different 
substituted  phenyl  attachments  at fifth position.   
           3,4-dihydropyrimidine with phenyl substitution at fourth position and different 
substituted phenyl attachments at sixth position. 
The resultant compounds of N-phenylpyrazoine and 3,4-dihydropyrimidine 
respectively from chalcone, will be evaluated for anti-oxidant, anti-diabetic, anti-
inflammatory and anti-tuberculosis activities.   
PLAN OF WORK: 
 Designing the molecules using software tools like Molinspiration & Chemdoodle. 
 Establishing the methods of synthesis for the  proposed compounds. 
 Carry out the  preliminary test for such as solubility, melting point, Rf-value etc. 
The synthesized compound structures are confirmed by spectrum analysis using 
FTIR, 1HNMR, and MASS spectra. 
 The compounds are screened for biological activities such as anti-oxidant, anti-
diabetic, anti-inflammatory and anti-tubercuosis activities.  
  
 
 
      EXPERIMENTAL WORK 
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4.EXPERIMENTAL WORK 
 
4.1 MOLECULAR DESIGN 
The Software tools like Chemdoodle, Molinspiration, Chemsketch were used to design 
the molecule for synthesis. 
A) Chemdoodle: 
       It is used to assess the LIPINSKI’S RULE. It is the rule of five used by LIPINSKI to 
improve the bioavailability of the drug. Lipinski rule states that the orally active drugs have: 
     
 Molecular weight   ≤ 500 
 logP     ≤ 5 
 hydrogen bond acceptors  ≤ 10     
 hydrogen bond donors  ≤ 5 
               
The molecules violating any one of the above rule will not have proper bio-availability. 
B) Molinspiration: 
         Virtual Screening is the computational chemistry technique to assess the large 
drug databases to identify the new drug molecules. It screens the molecules and 
provides the bioactivity score between -3 and 3. Molecules with highest bioactivity 
score will be more biologically active and produces better activity. 
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        C) Chemsketch: 
It is a software tool used for the prediction of molecular properties such as 
molecular mass, LogP, molar refractivity, parachor, molar volume, surface tension, 
polarizability and elemental composition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter IV                                                                       Experimental work                        
 
Department of Pharmaceutical Chemistry,MMC, MDU  Page 35 
 
LIPINSKI’S RULE PREDICTED BY CHEMDOODLE 
 
COMPOUND K1 
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          COMPOUND K2 
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COMOPOUND K3 
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COMPOUND K4 
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COMPOUND K5 
 
 
 
 
 
 
 
Molecular Formula = C21H18N2 
Molecular Mass =298.38 
Hydrogen Bond Acceptor Count = 3 
Hydrogen Bond Donor Count = 0 
Tb = 840 
Tf = 298 
XlogP v2.0 = 4.20 
CMR = 99 
AMR = 98.5 
Bioavailability Score = 0.15 
Lipinski’s Rule of Violations Count = 1 
www.chemdoodle.com 
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COMPOUND K6 
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COMPOUND K7 
                        
                                              
 
 
 
 
 
Chapter IV                                                                       Experimental work                        
 
Department of Pharmaceutical Chemistry,MMC, MDU  Page 42 
 
COMPOUND K8 
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COMPOUND K9 
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COMPOUND K10 
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                    BIOACTIVITY SCORE BY MOLINSPIRATION 
 
COMPOUND K1 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         5.937 
TPSA           15.602 
natoms         24.0 
MW             332.834 
nON            2 
nOHNH          0 
nviolations    1 
nrotb          3 
volume         299.229 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.30 
Ion channel modulator      -0.66 
Kinase inhibitor           -0.73 
Nuclear receptor ligand    -0.00 
Protease inhibitor         -0.64 
Enzyme inhibitor           -0.27 
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COMPOUND K2 
 
 
 
 
 
    
 
Molinspiration property engine v2013.09
 
miLogP         4.89 
TPSA           43.304 
natoms         29.0 
MW             388.467 
nON            5 
nOHNH          0 
nviolations    0 
nrotb          6 
volume         362.33 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.31 
Ion channel modulator      -0.64 
Kinase inhibitor           -0.62 
Nuclear receptor ligand    -0.08 
Protease inhibitor         -0.59 
Enzyme inhibitor           -0.25 
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COMPOUND K3 
 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         5.361 
TPSA           18.84 
natoms         26.0 
MW             341.458 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          4 
volume         331.599 
 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.27 
Ion channel modulator      -0.62 
Kinase inhibitor           -0.63 
Nuclear receptor ligand     0.04 
Protease inhibitor         -0.56 
Enzyme inhibitor           -0.23 
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COMPOUND K4 
 
 
  
 
 
 
Molinspiration property engine v2013.09
 
miLogP         5.316 
TPSA           24.836 
natoms         25.0 
MW             328.415 
nON            3 
nOHNH          0 
nviolations    1 
nrotb          4 
volume         311.238 
 
 
 
Molinspiration bioactivity score v2011.06
GPCR ligand                -0.34 
Ion channel modulator      -0.71 
Kinase inhibitor           -0.72 
Nuclear receptor ligand     0.00 
Protease inhibitor         -0.62 
Enzyme inhibitor           -0.28 
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COMPOUND K5 
 
 
 
 
Molinspiration property engine v2013.09
 
miLogP         5.259 
TPSA           15.602 
natoms         23.0 
MW             298.389 
nON            2 
nOHNH          0 
nviolations    1 
nrotb          3 
volume         285.693 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.32 
Ion channel modulator      -0.68 
Kinase inhibitor           -0.74 
Nuclear receptor ligand     0.02 
Protease inhibitor         -0.64 
Enzyme inhibitor           -0.25 
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COMPOUND K6 
 
 
 
  
 
 
Molinspiration property engine v2013.09 
miLogP         3.712 
TPSA           41.125 
natoms         20.0 
MW             284.746 
nON            3 
nOHNH          2 
nviolations    0 
nrotb          2 
volume         246.179 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.26 
Ion channel modulator      -0.36 
Kinase inhibitor           -0.63 
Nuclear receptor ligand    -0.65 
Protease inhibitor         -0.62 
Enzyme inhibitor           -0.46 
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COMPOUND K7 
 
 
  
 
Molinspiration property engine v2013.09 
 
miLogP         2.665 
TPSA           68.827 
natoms         25.0 
MW             340.379 
nON            6 
nOHNH          2 
nviolations    0 
nrotb          5 
volume         309.28  
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.18 
Ion channel modulator      -0.36 
Kinase inhibitor           -0.46 
Nuclear receptor ligand    -0.49 
Protease inhibitor         -0.48 
Enzyme inhibitor           -0.41 
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COMPOUND K8 
 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         3.136 
TPSA           44.363 
natoms         22.0 
MW             293.37 
nON            4 
nOHNH          2 
nviolations    0 
nrotb          3 
volume         278.549 
 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.18 
Ion channel modulator      -0.36 
Kinase inhibitor           -0.46 
Nuclear receptor ligand    -0.49 
Protease inhibitor         -0.48 
SEnzyme inhibitor           -0.41 
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COMPOUND K9 
 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         3.091 
TPSA           50.359 
natoms         21.0 
MW             280.327 
nON            4 
nOHNH          2 
nviolations    0 
nrotb          3 
volume         258.189  
 
 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.27 
Ion channel modulator      -0.43 
Kinase inhibitor           -0.59 
Nuclear receptor ligand    -0.57 
Protease inhibitor         -0.57 
Enzyme inhibitor           -0.45 
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COMPOUND K10 
 
 
  
 
 
Molinspiration property engine v2013.09 
 
miLogP         3.034 
TPSA           41.125 
natoms         19.0 
MW             250.301 
nON            3 
nOHNH          2 
nviolations    0 
nrotb          2 
volume         232.643 
 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.32 
Ion channel modulator      -0.37 
Kinase inhibitor           -0.68 
Nuclear receptor ligand    -0.70 
Protease inhibitor         -0.64 
Enzyme inhibitor           -0.45 
 
 
 
 
                               
Chapter IV                                                                       Experimental work                        
 
Department of Pharmaceutical Chemistry,MMC, MDU  Page 55 
 
MOLECULAR PROPERTIES USING CHEMSKETCH 
 
COMPOUND K1 
 
                             
N
N
Cl
5-(4-chlorophenyl)-1,3-diphenyl-4,5-dihydro-1H-pyrazole
Molecular Formula  = C21H17ClN2
Formula Weight  = 332.82608
Composition  =  C(75.78%) H(5.15%) Cl(10.65%) N(8.42%)
Molar Refractivity  = 100.74 ± 0.5 cm3
Molar Volume  = 281.3 ± 7.0 cm3
Parachor  = 728.7 ± 8.0 cm3
Index of Refraction  = 1.635 ± 0.05
Surface Tension  = 44.9 ± 7.0 dyne/cm
Density  = 1.18 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 39.93 ± 0.5 10-24cm3
Monoisotopic Mass  = 332.108026 Da
Nominal Mass  = 332 Da
Average Mass  = 332.8261 Da
M+  = 332.107478 Da
M-  = 332.108575 Da
[M+H]+  = 333.115303 Da
[M+H]-  = 333.1164 Da
[M-H]+  = 331.099653 Da
[M-H]-  = 331.10075 Da  
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COMPOUND K2 
 
 
                       
N
N
OCH3
OCH3
OCH3
5(3,4,5 trimethoxyphenyl)-1,3 -diphenyl -4,5 -dihydro -1Hpyrazole
Molecular Formula  = C24H24N2O3
Formula Weight  = 388.45896
Composition  =  C(74.21%) H(6.23%) N(7.21%) O(12.36%)
Molar Refractivity  = 113.58 ± 0.5 cm3
Molar Volume  = 337.0 ± 7.0 cm3
Parachor  = 850.6 ± 8.0 cm3
Index of Refraction  = 1.588 ± 0.05
Surface Tension  = 40.5 ± 7.0 dyne/cm
Density  = 1.15 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 45.02 ± 0.5 10-24cm3
Monoisotopic Mass  = 388.178693 Da
Nominal Mass  = 388 Da
Average Mass  = 388.459 Da
M+  = 388.178144 Da
M-  = 388.179241 Da
[M+H]+  = 389.185969 Da
[M+H]-  = 389.187066 Da
[M-H]+  = 387.170319 Da
[M-H]-  = 387.171416 Da  
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COMPOUND K3 
 
                        
                             
N
N
N
CH3
CH3
4-(1,3-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)-N,N-dimethylaniline
Molecular Formula  = C23H23N3
Formula Weight  = 341.44882
Composition  =  C(80.90%) H(6.79%) N(12.31%)
Molar Refractivity  = 108.94 ± 0.5 cm3
Molar Volume  = 313.2 ± 7.0 cm3
Parachor  = 796.1 ± 8.0 cm3
Index of Refraction  = 1.612 ± 0.05
Surface Tension  = 41.7 ± 7.0 dyne/cm
Density  = 1.09 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 43.18 ± 0.5 10-24cm3
Monoisotopic Mass  = 341.189198 Da
Nominal Mass  = 341 Da
Average Mass  = 341.4488 Da
M+  = 341.188649 Da
M-  = 341.189746 Da
[M+H]+  = 342.196474 Da
[M+H]-  = 342.197571 Da
[M-H]+  = 340.180824 Da
[M-H]-  = 340.181921 Da  
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COMPOUND K4 
 
                                   
N
N
OCH3
5-(4-methoxyphenyl)-1,3-diphenyl-4,5-dihydro-1H-pyrazole
Molecular Formula  = C22H20N2O
Formula Weight  = 328.407
Composition  =  C(80.46%) H(6.14%) N(8.53%) O(4.87%)
Molar Refractivity  = 101.95 ± 0.5 cm3
Molar Volume  = 293.7 ± 7.0 cm3
Parachor  = 750.1 ± 8.0 cm3
Index of Refraction  = 1.610 ± 0.05
Surface Tension  = 42.5 ± 7.0 dyne/cm
Density  = 1.11 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 40.41 ± 0.5 10-24cm3
Monoisotopic Mass  = 328.157563 Da
Nominal Mass  = 328 Da
Average Mass  = 328.407 Da
M+  = 328.157015 Da
M-  = 328.158112 Da
[M+H]+  = 329.16484 Da
[M+H]-  = 329.165937 Da
[M-H]+  = 327.14919 Da
[M-H]-  = 327.150287 Da  
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COMPOUND K5 
 
                                 
N
N
1,3,5-triphenyl-4,5-dihydro-1H-pyrazole
Molecular Formula  = C21H18N2
Formula Weight  = 298.38102
Composition  =  C(84.53%) H(6.08%) N(9.39%)
Molar Refractivity  = 96.14 ± 0.5 cm3
Molar Volume  = 272.0 ± 7.0 cm3
Parachor  = 699.8 ± 8.0 cm3
Index of Refraction  = 1.624 ± 0.05
Surface Tension  = 43.7 ± 7.0 dyne/cm
Density  = 1.09 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 38.11 ± 0.5 10-24cm3
Monoisotopic Mass  = 298.146999 Da
Nominal Mass  = 298 Da
Average Mass  = 298.381 Da
M+  = 298.14645 Da
M-  = 298.147547 Da
[M+H]+  = 299.154275 Da
[M+H]-  = 299.155372 Da
[M-H]+  = 297.138625 Da
[M-H]-  = 297.139722 Da  
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COMPOUND K6 
 
             
                                
NH NH
O
Cl
6-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one
Molecular Formula  = C16H13ClN2O
Formula Weight  = 284.74022
Composition  =  C(67.49%) H(4.60%) Cl(12.45%) N(9.84%) O(5.62%)
Molar Refractivity  = 78.65 ± 0.3 cm3
Molar Volume  = 226.6 ± 3.0 cm3
Parachor  = 588.8 ± 6.0 cm3
Index of Refraction  = 1.610 ± 0.02
Surface Tension  = 45.5 ± 3.0 dyne/cm
Density  = 1.256 ± 0.06 g/cm3
Dielectric Constant  = Not available
Polarizability  = 31.18 ± 0.5 10-24cm3
Monoisotopic Mass  = 284.071641 Da
Nominal Mass  = 284 Da
Average Mass  = 284.7402 Da
M+  = 284.071092 Da
M-  = 284.072189 Da
[M+H]+  = 285.078917 Da
[M+H]-  = 285.080014 Da
[M-H]+  = 283.063267 Da
[M-H]-  = 283.064364 Da  
 
 
 
 
 
Chapter IV                                                                       Experimental work                        
 
Department of Pharmaceutical Chemistry,MMC, MDU  Page 61 
 
 
COMPOUND K7 
 
 
                                
NH NH
O
OCH3
OCH3
OCH3
4-phenyl-6-(3,4,5-trimethoxyphenyl)-3,4-dihydropyrimidin-2(1H)-one
Molecular Formula  = C19H20N2O4
Formula Weight  = 340.3731
Composition  =  C(67.05%) H(5.92%) N(8.23%) O(18.80%)
Molar Refractivity  = 93.79 ± 0.3 cm3
Molar Volume  = 286.6 ± 3.0 cm3
Parachor  = 727.6 ± 6.0 cm3
Index of Refraction  = 1.568 ± 0.02
Surface Tension  = 41.4 ± 3.0 dyne/cm
Density  = 1.187 ± 0.06 g/cm3
Dielectric Constant  = Not available
Polarizability  = 37.18 ± 0.5 10-24cm3
Monoisotopic Mass  = 340.142307 Da
Nominal Mass  = 340 Da
Average Mass  = 340.3731 Da
M+  = 340.141759 Da
M-  = 340.142856 Da
[M+H]+  = 341.149584 Da
[M+H]-  = 341.150681 Da
[M-H]+  = 339.133933 Da
[M-H]-  = 339.135031 Da  
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COMPOUND K8 
 
 
                              
NH NH
O
N
CH3
CH3
6-[4-(dimethylamino)phenyl]-4-phenyl-3,4-dihydropyrimidin-2(1H)-one
Molecular Formula  = C18H19N3O
Formula Weight  = 293.36296
Composition  =  C(73.69%) H(6.53%) N(14.32%) O(5.45%)
Molar Refractivity  = 88.07 ± 0.3 cm3
Molar Volume  = 252.6 ± 3.0 cm3
Parachor  = 656.4 ± 6.0 cm3
Index of Refraction  = 1.614 ± 0.02
Surface Tension  = 45.5 ± 3.0 dyne/cm
Density  = 1.161 ± 0.06 g/cm3
Dielectric Constant  = Not available
Polarizability  = 34.91 ± 0.5 10-24cm3
Monoisotopic Mass  = 293.152812 Da
Nominal Mass  = 293 Da
Average Mass  = 293.363 Da
M+  = 293.152264 Da
M-  = 293.153361 Da
[M+H]+  = 294.160089 Da
[M+H]-  = 294.161186 Da
[M-H]+  = 292.144439 Da
[M-H]-  = 292.145536 Da  
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COMPOUND K9  
 
 
                         
NH NH
O
OCH3
6-(4-methoxyphenyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one
Molecular Formula  = C17H16N2O2
Formula Weight  = 280.32114
Composition  =  C(72.84%) H(5.75%) N(9.99%) O(11.42%)
Molar Refractivity  = 80.44 ± 0.3 cm3
Molar Volume  = 238.6 ± 3.0 cm3
Parachor  = 610.3 ± 6.0 cm3
Index of Refraction  = 1.589 ± 0.02
Surface Tension  = 42.7 ± 3.0 dyne/cm
Density  = 1.174 ± 0.06 g/cm3
Dielectric Constant  = Not available
Polarizability  = 31.88 ± 0.5 10-24cm3
Monoisotopic Mass  = 280.121178 Da
Nominal Mass  = 280 Da
Average Mass  = 280.3211 Da
M+  = 280.120629 Da
M-  = 280.121726 Da
[M+H]+  = 281.128454 Da
[M+H]-  = 281.129551 Da
[M-H]+  = 279.112804 Da
[M-H]-  = 279.113901 Da  
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COMPOUND K10 
 
 
                             
NH NH
O
4,6-diphenyl-3,4-dihydropyrimidin-2(1H)-one
Molecular Formula  = C16H14N2O
Formula Weight  = 250.29516
Composition  =  C(76.78%) H(5.64%) N(11.19%) O(6.39%)
Molar Refractivity  = 73.76 ± 0.3 cm3
Molar Volume  = 214.6 ± 3.0 cm3
Parachor  = 551.7 ± 6.0 cm3
Index of Refraction  = 1.603 ± 0.02
Surface Tension  = 43.6 ± 3.0 dyne/cm
Density  = 1.165 ± 0.06 g/cm3
Dielectric Constant  = Not available
Polarizability  = 29.24 ± 0.5 10-24cm3
Monoisotopic Mass  = 250.110613 Da
Nominal Mass  = 250 Da
Average Mass  = 250.2952 Da
M+  = 250.110064 Da
M-  = 250.111162 Da
[M+H]+  = 251.11789 Da
[M+H]-  = 251.118987 Da
[M-H]+  = 249.102239 Da
[M-H]-  = 249.103337 Da  
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TABLE-1:  LIST OF CHEMICALS USED 
      
 
S.N0                     NAME OF CHEMICALS 
 
MANUFATURER 
1 Acetophenone Sigma Aldrich 
2 Benzophenone Sigma Aldrich 
3 Benzaldehyde CDH Lab 
4 P-dimethylamino benzaldehyde CDH Lab 
5 P-chloro benzaldehyde CDH Lab 
6 Anisaldehyde CDH Lab 
7 3,4,5-trimethoxy benzaldehyde Sigma Aldrich 
8 Ethanol HPLC 
9 Urea HPLC 
10 Sodium hydroxide CDH Lab 
11 Glacial acetic acid CDH Lab 
12 Concentrated sulfuric acid CDH Lab 
13 Dioxane CDH Lab 
14 Potassium hydroxide HPLC 
 
 
 
 
 
 
 
 
 
Chapter IV                                                                       Experimental work                        
 
Department of Pharmaceutical Chemistry,MMC, MDU  Page 66 
 
                                    4.2- SCHEME OF SYNTHESIS 
 SCHEME OF REACTION-I ( Synthesis of compound K1-K5) 
                             
CH3
O
+
Ar
-
O
NH
NH2
glacial acetic acid
NaOHEthanol
1-phenylethanone
phenylhydrazine
STEP 1
STEP 2
Ar - CHO
Substituted benzaldehye
N
N
Ar
-
2E -1phenyl -3substituted prop -2en -1one
5- aryl 1,3 -diphenyl 4,5 -diyhdro -1H - Pyrazole 
 
 
Chapter IV                                                                       Experimental work                        
 
Department of Pharmaceutical Chemistry,MMC, MDU  Page 67 
 
SCHEME OF REACTION-II 
SYNTHESIS OF COMPOUND-K6-K10 
                           
CH3
O
+
Ar
-
O
NH NH
Ar
-
O
NaOHEthanol
1-phenylethanone
NH2 NH2
O
urea
Ethanol
10% KOH
Ar - CHO
2(E)-1 -phenyl -3 -substituted prop -2en -1one
2(E)-1 -phenyl -3 -substituted prop -2en -1one
Substituted bezaldehyde
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4.3 MOLECULAR SYNTHESIS37,54 
 
 
  
Synthesis of Compound K1 
 
                                                            STEP- 1 
                         
Synthesis of (2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
  
Acetophenone   - 0.01M 
  4-chloro benzaldehyde   - 0.01M 
Ethanol   - 20ml 
Sodium hydroxide   - 0.01M  
Dilute Hydrochloric acid   - 0.01M 
 
Procedure: 
 
The solution of acetophenone (0.01M) and 4-chloro benzaldehyde (0.01M)  in 
ethanol(20ml) at room temperature was add sodium hydroxide (0.01M) with constant  
stirring. The reaction mixture was stirred further until a precipitate was formed. The reaction 
mixture was diluted with ice water and neutralized by using (0.01M) diliuted hydrochloric 
acid. The product was filtered and recrystallized from ethanol.   
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                                                            STEP – 2 
 
Synthesis of 5-(4-chlorophenyl)-1,3-diphenyl-4,5-dihydro-1H-Pyrazole 
 
Chemicals Required: 
 
 (2E)-3-(4-chlorophenyl)-1-phenyl prop-2-en-1- one  -  0.008mol. 
1,4-Dioxane        - 20ml. 
Phenyl hydrazine      - 0.024mol. 
Cocentrated Sulphuric acid      - 2-3 drops. 
Glacial Acetic acid       - 5ml. 
 
Procedure:  
To (2E)-3-(4-chlorophenyl)-1-phenyl prop-2-en-1- one (0.0084)  20ml of 1,4-Dioxane 
and Phenyl hydrazine (0.024Mol) was added. To these mixture 2-3 drops of  Sulphuric acid 
was added and the contents was allowed to get reflux for 4hrs. 5ml of  glacial acetic acid was 
added; again reflux was done for next 2hrs. On cooling to room  temperature the contents was 
poured on crushed ice. As a result the solid product was obtained which was recrystallized by 
using ethanol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter IV                                                                       Experimental work                        
 
Department of Pharmaceutical Chemistry,MMC, MDU  Page 70 
 
COMPOUND K1 
 
                   
CH3
O
+
Cl
OHC
NaOHEthanol
O
Cl
NH
NH2
N
N
Cl
STEP 2
STEP 1
1-phenylethanone 4-chlorobenzaldehyde
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
phenylhydrazine
5-(4-chlorophenyl)-1,3-diphenyl-4,5-dihydro-1H-pyrazole
glacial acetic acid
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Synthesis of Compound K2 
                                                             STEP- 1 
Synthesis of (2E)-3-(3,4,5-methoxyphenyl)-1-phenyl prop-2-en-1- one (Chalcone) 
 
Chemicals Required: 
   Acetophenone    - 0.01M 
   3,4,5- Trimethoxy benzaldehyde   - 0.01M 
Ethanol     - 20ml 
Sodium hydroxide     - 0.01M  
Dilute Hydrochloric acid   - 0.01M 
 
Procedure: 
 
The solution of acetophenone (0.01M) and 3,4,5- Trimethoxy  benzaldehyde (0.01M)  
in ethanol(20ml) at room temperature was add sodium hydroxide  (0.01M) with constant 
stirring. The reaction mixture was stirred further until a precipitate was formed. The reaction 
mixture was diluted with ice water and neutralized by using (0.01M) diliuted hydrochloric 
acid. The product was filtered and recrystallized from ethanol.  
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                                                           STEP – 2 
 
Synthesis of 5-(3,4,5-metoxyphenyl)-1,3-diphenyl-4,5-dihydro-1H-Pyrazole. 
 
 
Chemicals Required: 
 
 
(2E)-3-(3,4,5-methoxyphenyl)-1-phenyl prop-2-en-1- one    -  0.008mol. 
1,4-Dioxane         - 20ml. 
Phenyl hydrazine       - 0.024mol. 
Cocentrated Sulphuric acid      - 2-3 drops. 
Glacial Acetic acid        - 5ml. 
 
Procedure:  
 
 
To (2E)-3-(3,4,5-methoxyphenyl)-1-phenyl prop-2-en-1- one (0.0084)  20ml of 1,4-
Dioxane and Phenyl hydrazine (0.024Mol) was added. To these mixture 2-3  drops of 
Sulphuric acid was added and the contents was allowed to get reflux for 4hrs. 5ml of glacial 
acetic acid was added; again reflux was done for next 2hrs. On cooling to room temperature 
the contents was poured on crushed ice. As a result the solid product was obtained which was 
recrystallized by using ethanol.  
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COMPOUND K2 
CH3
O
+
Cl
OHC
NaOHEthanol
O
Cl
NH
NH2
N
N
Cl
STEP 2
STEP 1
1-phenylethanone 4-chlorobenzaldehyde
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
phenylhydrazine
5-(4-chlorophenyl)-1,3-diphenyl-4,5-dihydro-1H-pyrazole
glacial acetic acid
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Synthesis of Compound K3 
 
STEP- 1 
 
Synthesis of (2E)-3-(4-(dimethylamino)phenyl)-1-phenylprop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
  
Acetophenone     - 0.01M 
4-dimethyl benzaldehyde   - 0.01M 
Ethanol     - 20ml 
Sodium hydroxide     - 0.01M  
Dilute Hydrochloric acid  - 0.01M 
 
 
Procedure: 
 
 
The solution of acetophenone (0.01M) and 4-dimethylamino benzaldehyde (0.01M) in 
ethanol(20ml) at room temperature was add sodium hydroxide  (0.01M) with constant 
stirring. The reaction mixture was stirred further until a precipitate was formed. The reaction 
mixture was diluted with ice water and neutralized  by using (0.01M) diliuted hydrochloric 
acid. The product was filtered and recrystallized  from ethanol.   
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                                                STEP – 2 
 
Synthesis of  5-(4-(dimethyl amino)phenyl)-1,3-diphenyl-4,5-dihydro-1H-Pyrazole. 
 
 
Chemicals Required: 
 
 
(2E)-3-(4-(dimethyl amino)phenyl)-1-phenyl prop-2-en-1- one   -  0.008mol. 
1,4-Dioxane         - 20ml. 
Phenyl hydrazine         - 0.024mol. 
Cocentrated Sulphuric acid         - 2-3 drops. 
Glacial Acetic acid         - 5ml. 
 
Procedure:  
 
 
To (2E)-3-(4-(dimethyl amino)phenyl)-1-phenyl prop-2-en-1- one  (0.0084)  20ml of 
1,4-Dioxane and Phenyl hydrazine (0.024Mol) was added. To these  mixture 2-3  drops of 
Sulphuric acid was added and the contents was allowed to get reflux for 4hrs. 5ml of glacial 
acetic acid was added; again reflux was done for next 2hrs. On cooling to room temperature 
the contents was poured on crushed ice. As a result the solid product was obtained which was 
recrystallized by using ethanol.  
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COMPOUND K3 
                         
CH3
O
+
OHC
N
CH3
CH3
O
N CH3
CH3
N
N
N
CH3
CH3
NH
NH2
glacial acetic acid
STEP 2
STEP 1
NaOHEthanol
1-phenylethanone
(2E)-3-[4-(dimethylamino)phenyl]-1-phenylprop-2-en-1-one
phenylhydrazine
4-(1,3-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)-N,N-dimethylaniline
4-(dimethylamino)benzaldehyde
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Synthesis of Compound K4 
 
                                                              STEP- 1 
 
Synthesis of (2E)-3-(4-metoxyphenyl)-1-phenylprop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
   Acetophenone   - 0.01M 
4-methoxy benzaldehyde - 0.01M 
Ethanol    - 20ml 
Sodium hydroxide    - 0.01M  
Dilute Hydrochloric acid - 0.01M 
 
Procedure: 
 
 
The solution of acetophenone (0.01M) and 4-methoxy benzaldehyde (0.01M) in 
ethanol(20ml) at room temperature was add sodium hydroxide (0.01M) with constant stirring. 
The reaction mixture was stirred further until a precipitate was formed. The reaction mixture 
was diluted with ice water and neutralized by using (0.01M) diliuted hydrochloric acid. The 
product was filtered and recrystallized from ethanol.   
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                                                            STEP – 2 
 
 
Synthesis of  5-(4-methoxyphenyl)-1,3-diphenyl-4,5-dihydro-1H-Pyrazole. 
 
 
Chemicals Required: 
 
(2E)-3-(4- methoxyphenyl)-1-phenyl prop-2-en-1- one  - 0.008mol. 
1,4-Dioxane        - 20ml. 
Phenyl hydrazine        - 0.024mol. 
Cocentrated Sulphuric acid      - 2-3 drops. 
Glacial Acetic acid       - 5ml. 
 
Procedure:  
 
To (2E)-3-(4-methoxyphenyl)-1-phenyl prop-2-en-1- one (0.0084)  20ml of 1,4-
Dioxane and Phenyl hydrazine (0.024Mol) was added. To these mixture 2-3  drops of 
Sulphuric acid was added and the contents was allowed to get reflux for 4hrs. 5ml of glacial 
acetic acid was added; again reflux was done for next 2hrs. On cooling to room temperature 
the contents was poured on crushed ice. As a result the solid product was obtained which was 
recrystallized by using ethanol.  
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 COMPOUND K4 
 
CH3
O
+
OCH3
OHC
O
OCH3
N
N
OCH3
NH
NH2
glacial acetic acid
STEP 2
STEP 1
NaOHEthanol
1-phenylethanone 4-methoxybenzaldehyde
phenylhydrazine
5-(4-methoxyphenyl)-1,3-diphenyl-4,5-dihydro-1H-pyrazole
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
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Synthesis of Compound K5 
 
STEP- 1 
 
Synthesis of (2E)-1,3-diphenylprop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
  
Acetophenone   - 0.01M 
benzaldehyde    - 0.01M 
Ethanol      - 20ml 
Sodium hydroxide    - 0.01M  
Dilute Hydrochloric acid - 0.01M 
 
Procedure: 
 
The solution of acetophenone (0.01M) and  benzaldehyde (0.01M) in ethanol(20ml) at 
room temperature was add sodium hydroxide (0.01M) with constant stirring. The reaction 
mixture was stirred further until a precipitate was formed. The reaction mixture was diluted 
with ice water and neutralized by using (0.01M) diliuted hydrochloric acid. The product was 
filtered and recrystallized from ethanol.   
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STEP – 2 
 
Synthesis of  1,3,5-triphenyl-4,5-dihydro-1H-Pyrazole. 
 
 
Chemicals Required: 
 
(2E)-1,3-diphenyl prop-2-en-1- one    -  0.008mol. 
1,4-Dioxane      - 20ml. 
Phenyl hydrazine     - 0.024mol. 
Cocentrated Sulphuric acid    - 2-3 drops. 
Glacial Acetic acid      - 5ml. 
 
Procedure:  
 
 
To (2E)-1,3-diphenyl prop-2-en-1- one (0.0084)  20ml of 1,4-Dioxane and Phenyl 
hydrazine (0.024Mol) was added. To these mixture 2-3  drops of Sulphuric acid was added 
and the contents was allowed to get reflux for 4hrs. 5ml of glacial acetic acid was added; 
again reflux was done for next 2hrs. On cooling to room temperature the contents was poured 
on crushed ice. As a result the solid product was obtained which was recrystallized by using 
ethanol.  
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COMPOUND K5 
                      
CH3
O
+
OHC
O
NaOHEthanol
NH NH2
glacial acetic acid
N
N
1-phenylethanone benzaldehyde
(2E)-1,3-diphenylprop-2-en-1-one
phenylhydrazine
1,3,5-triphenyl-4,5-dihydro-1H-pyrazole  
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Synthesis of Compound K6 
 
STEP- 1 
 
Synthesis of (2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
  
Acetophenone                - 0.01M 
4-chloro benzaldehyde   - 0.01M 
Ethanol      - 20ml 
Sodium hydroxide     - 0.01M  
Dilute Hydrochloric acid   - 0.01M 
 
Procedure: 
 
 
The solution of acetophenone (0.01M) and 4-chloro benzaldehyde (0.01M)  in 
ethanol(20ml) at room temperature was add sodium hydroxide (0.01M) with constant  
stirring. The reaction mixture was stirred further until a precipitate was formed. The reaction 
mixture was diluted with ice water and neutralized by using (0.01M) diliuted hydrochloric 
acid. The product was filtered and recrystallized from ethanol.   
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STEP -2 
Syntheisis of 6-(4-chlorophenyl)-4-phenyl-3,4-dihydro pyrimidine-2(1H)-one. 
 
Chemicals Required: 
  
              (2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1- one   -  0.01mol. 
 Urea        -  0.01mol. 
 Ethanol         -  25ml. 
 10% Potassium  hydroxide     -  5ml. 
 
Procedure: 
 A mixture of  (2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1- one    (0.01mol), 
Urea(0.01mol) in absolute ethanol(25ml) and 10% potassium hydroxide(5ml) refluxed on a 
waterbath for 8hours. The reaction was monitered by TLC and the precipitation was 
recrystalised from absolute ethanol give pure compound. 
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COMPOUND K6 
                              
CH3
O
+
Cl
OHC
O
Cl
NH NH
O
Cl
NaOHEthanol
4-chlorobenzaldehyde1-phenylethanone
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
NH2 NH2
O
urea
Ethanol
10% KOH
6-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one  
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Synthesis of Compound K7 
 
 
STEP- 1 
 
Synthesis of (2E)-3-(3,4,5-methoxyphenyl)-1-phenyl prop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
  
 
Acetophenone    - 0.01M 
3,4,5- Trimethoxy benzaldehyde  - 0.01M 
Ethanol     - 20ml 
Sodium hydroxide     - 0.01M  
Dilute Hydrochloric acid   - 0.01M 
 
Procedure: 
  
The solution of acetophenone (0.01M) and 3,4,5- Trimethoxy  benzaldehyde (0.01M)  
in ethanol(20ml) at room temperature was add sodium hydroxide  (0.01M) with constant 
stirring. The reaction mixture was stirred further until a precipitate was formed. The reaction 
mixture was diluted with ice water and neutralized by using (0.01M) diliuted hydrochloric 
acid. The product was filtered and recrystallized from ethanol.  
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STEP – 2 
Synthesis of 4-(phenyl-6-(3,4,5-trimethoxy phenyl)-3,4-dihydropyrimidin-2(1H)-one. 
 
Chemicals Required: 
(2E)-3-(3,4,5-methoxyphenyl)-1-phenyl prop-2-en-1- one  -  0.01mol. 
Urea         -  0.01mol . 
Ethanol         -  25ml. 
10% Potassium hydroxide       -  5ml. 
 
Procedure: 
 A mixture of   (2E)-3-(3,4,5-methoxyphenyl)-1-phenyl prop-2-en-1- one 
(0.01mol), Urea(0.01mol) in absolute ethanol(25ml) and 10% potassium hydroxide(5ml) 
refluxed on a waterbath for 8hours. The reaction was monitered by TLC and the precipitation 
was recrystalised from absolute ethanol give pure compound. 
 
 
                 
 
 
 
 
 
 
 
 
Chapter IV                                                                       Experimental work                        
 
Department of Pharmaceutical Chemistry,MMC, MDU  Page 88 
 
 
COMPOUND K7 
                        
CH3
O
+
OCH3
OCH3
OCH3OHC
O
OCH3
OCH3
OCH3
NH NH
O
OCH3
OCH3
OCH3
NH2
NH2
O
STEP 2
NaOHEthanol
STEP 1
1-phenylethanone 3,4,5-trimethoxybenzaldehyde
(2E)-1-phenyl-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
4-phenyl-6-(3,4,5-trimethoxyphenyl)-3,4-dihydropyrimidin-2(1H)-one
urea
Ethanol
10% KOH
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Synthesis of Compound K8 
 
STEP- 1 
 
Synthesis of (2E)-3-(4-(dimethylamino)phenyl)-1-phenylprop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
  
 
Acetophenone      - 0.01M 
  4-dimethyl benzaldehyde    - 0.01M 
Ethanol       - 20ml 
  Sodium hydroxide      - 0.01M  
Dilute Hydrochloric acid   - 0.01M 
 
 
Procedure: 
 
The solution of acetophenone (0.01M) and 4-dimethylamino benzaldehyde (0.01M) 
in ethanol(20ml) at room temperature was add sodium hydroxide  (0.01M) with constant 
stirring. The reaction mixture was stirred further until a precipitate was formed. The reaction 
mixture was diluted with ice water and neutralized  by using (0.01M) diliuted hydrochloric 
acid. The product was filtered and recrystallized  from ethanol.   
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                                                STEP – 2 
 
Synthesis of 6-[4-(dimethylamino)phenyl]-4-phenyl-3,4-dihydropyrimidin-2(1H)-one. 
 
Chemicals Required: 
 
 (2E)-3-(4-(dimethylamino)phenyl)-1-phenylprop-2-en-1- one  -  0.01mol. 
Urea            -  0.01mol . 
Ethanol          -  25ml. 
10% Potassium hydroxide       -  5ml. 
 
 
Procedure: 
  
              A mixture of   (2E)-3-(4-(dimethylamino)phenyl)-1-phenylprop-2-en-1- one 
(0.01mol), Urea(0.01mol) in absolute ethanol(25ml) and 10% potassium hydroxide(5ml) 
refluxed on a waterbath for 8hours. The reaction was monitered by TLC and the precipitation 
was recrystalised from absolute ethanol give pure compound. 
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COMPOUND K8 
                         
CH3
O
+
OHC
N
CH3
CH3
NaOHEthanol
OH
N CH3
CH3
STEP 1
NH NH
O
N
CH3
CH3
STEP 2
NH2 NH2
O
1-phenylethanone 4-(dimethylamino)benzaldehyde
(2E)-3-[4-(dimethylamino)phenyl]-1-phenylprop-2-en-1-ol
urea
6-[4-(dimethylamino)phenyl]-4-phenyl-3,4-dihydropyrimidin-2(1H)-one
Ethanol
10% KOH
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Synthesis of Compound K9 
 
                                                   STEP- 1 
 
Synthesis of (2E)-3-(4-metoxyphenyl)-1-phenylprop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
 
            Acetophenone               - 0.01M 
  4-methoxy benzaldehyde    - 0.01M 
Ethanol        - 20ml 
   Sodium hydroxide    - 0.01M  
Dilute Hydrochloric acid   - 0.01M 
 
 
Procedure: 
 
The solution of acetophenone (0.01M) and 4-methoxy benzaldehyde (0.01M) in 
ethanol(20ml) at room temperature was add sodium hydroxide (0.01M) with constant stirring. 
The reaction mixture was stirred further until a precipitate was formed. The reaction mixture 
was diluted with ice water and neutralized by using (0.01M) diliuted hydrochloric acid. The 
product was filtered and recrystallized from ethanol.   
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                                                 STEP – 2 
Synthesis of  6-(4-methoxyphenyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one. 
 
Chemicals Required: 
 
(2E)-3-(4-metoxyphenyl)-1-phenylprop-2-en-1- one  -  0.01mol. 
Urea          -  0.01mol . 
Ethanol         -  25ml. 
10% Potassium hydroxide       -  5ml. 
 
Procedure: 
  
              A mixture of (2E)-3-(4-metoxyphenyl)-1-phenylprop-2-en-1- one (0.01mol), 
Urea(0.01mol) in absolute ethanol(25ml) and 10% potassium hydroxide(5ml) refluxed on a 
waterbath for 8hours. The reaction was monitered by TLC and the precipitation was 
recrystalised from absolute ethanol give pure compound. 
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COMPOUND K9 
                     
CH3
O
+
OCH3
OHC
NaOHEthanol
O
OCH3
NH2 NH2
O
NH NH
OCH3
O
STEP 2
STEP 1
1-phenylethanone 4-methoxybenzaldehyde
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
6-(4-methoxyphenyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one
urea
Ethanol
10% KOH
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Synthesis of Compound K10 
 
STEP- 1 
 
Synthesis of (2E)-1,3-diphenylprop-2-en-1- one (Chalcone) 
 
 
Chemicals Required: 
  
Acetophenone     - 0.01M 
benzaldehyde     - 0.01M 
Ethanol      - 20ml 
Sodium hydroxide    - 0.01M  
Dilute Hydrochloric acid    - 0.01M 
 
Procedure: 
 
 
The solution of acetophenone (0.01M) and  benzaldehyde (0.01M) in ethanol(20ml) at 
room temperature was add sodium hydroxide (0.01M) with constant stirring. The reaction 
mixture was stirred further until a precipitate was formed. The reaction mixture was diluted 
with ice water and neutralized by using (0.01M) diliuted hydrochloric acid. The product was 
filtered and recrystallized from ethanol.   
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STEP – 2 
Synthesis of 4,6-diphenyl-3,4-dihydropyrimidin-2(1H)-one. 
 
Chemicas Required: 
 
(2E)-1,3-diphenylprop-2-en-1- one  -  0.01mol. 
Urea       -  0.01mol . 
Ethanol      -  25ml. 
10% Potassium hydroxide   -  5ml. 
 
Procedure: 
 
 A mixture of (2E)-1,3-diphenylprop-2-en-1- one (0.01mol), Urea(0.01mol) in 
absolute ethanol(25ml) and 10% potassium hydroxide(5ml) refluxed on a waterbath for 
8hours. The reaction was monitered by TLC and the precipitation was recrystalised from 
absolute ethanol give pure compound. 
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 COMPOUND K10 
                  
CH3
O
+
OHC
NaOHEthanol
O
NH NH
O
NH2 NH2
O
STEP 2
STEP 1
1-phenylethanone benzaldehyde
(2E)-1,3-diphenylprop-2-en-1-one
urea
4,6-diphenyl-3,4-dihydropyrimidin-2(1H)-one
Ethanol
10% KOH
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                              4.4  ANALYTICAL TECHNIQUES39,46 
Physical data  
The physical data such as solubility and melting point was determined. The 
compound was soluble in DMSO, Chloroform and insoluble in water. 
The melting point of synthesized compounds were determined by the capillary tube 
method. 
Thin Layer chromatography(TLC) 
TLC analysis was carried out on commercially available silica gel plates of 0.5mm of 
thickness, as stationary phase. Benzene:chloroform (9:1) mobile phase was used for n-
phenylpyrazoline derivatives. N-Hexane:Ethyl acetate (1:1) mobile phase was used for 3,4-
dihydropyrimidine derivatives. 
Instrumentation 
The analytical instruments such as IR spectra, 1HNMR, MASS spectra were used for 
the characterization of synthesized compounds. 
Infrared Spectra 
The IR spectra of synthesized compounds K1-K10 were recorded by FTIR (Shimadzu 
IR affinity I) in the range of 4000-450cm-1. 
Nuclear Magnetic Resonance 
The bruker Avance II 400 NMR spectrometer is used to measure the chemical shift 
and reported in parts per million (δ ppm). 
Mass spectroscopy 
The molecular ion peaks are recorded by Mass spectroscopy and reported in m/z ratio. 
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                                     4.5-BIOLOGICAL EVALUATION 
A. INVTIRO   ANTI-OXIDANT ACTIVITY 
Evaluation of antioxidant capacity by phosphomolybdenum method: 
Materials and method 
Equipment: 
UV spectrophotometer and thermostatically controlled water bath. 
Reagents:   
Sodium Phosphate 28mM 
Ammonium molybdate 4mM 
0.06M Sulphuric acid 
Ethanol 
Drugs:   
Standard drugs: Different concentration of Ascorbic acid 
Test drug        : Different concentration of compounds K1-K10. 
 
Procedure: 
 
Anti-oxidant activity was performed by the following procedure of Hance EI Hajaji et 
al (46). The antioxidant activity of the compounds was evaluated by the 
Phosphomolybdenum method. The assay is based on the reduction of Mo (VI) – Mo (V) by 
the compounds and subsequent formation of a green phosphate /Mo (V) complex at acid pH. 
A 0.3ml of compounds (100μg/ml, 200μg/ml and 300μg/ml) was combined with 3ml of 
reagent solution (0.6M sulfuric acid, 28mM sodium phosphate and 4mM ammonium 
molybdate). In case of blank 0.3ml of ethanol was used in place of compounds.  The tuves 
containing the reaction solution were capped and incubated in a boiling water bath at 95 ӷ C 
for 90 min. After cooling to room temperature, the absorbance of the solution was measured 
at 695nm using a UV spectrophotometer. The antioxidant capacity of each sample was 
compared with the absorbance of standard.   
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B. IN-VITRO ANTI-INFLAMMATORY ACTIVITY 
 
Evaluation of Anti-inflammatory activity by Membrane Stabilization Assay 
 
Instrument: 
 Shimadzu UV Visible spectrophotometer, Model 1800 
Reagents: 
0.2M sodium phosphate buffer (pH 7.4) 
0.36% w/v hyposaline 
10%v/v HRBC suspension in isosaline 
Preparation of HRBC suspension in isosaline: 
The human erythrocytes suspension was used for the in vitro membrane stabilization 
assay. Blood was collected from healthy volunteers who had not consumed any NSAIDs for 
two weeks prior to the experiment. The blood was mixed with equal volume of Alsever 
solution (2% dextrose, 8.0% sodium citrate, 0.5% citric acid and 0.42% sodium chloride) and 
centrifuged at 3000rpm. The packed cells were washed with isosaline and a 10% v/v 
erythrocyte suspension in isosaline was prepared.  
Procedure: 
 The assay mixture consist of 2mL of hyposaline and 1mL of phosphate buffer and 
varying concentration of compounds (200μg/ml, 400μg/ml, 600μg/ml) 0.5 mL and 0.5mL of 
HRBC suspension in isosaline, then the final volume were made up with isosaline up to 
4.5mL. The control was prepared as mentioned above except the drug was omitted, while 
drug control was also prepared similarly but without HRBC suspension. The reaction mixture 
was incubated at 56ºC for 30min in a water bath, then the tube was cooled under running 
water. Then the absorbance of the released haemoglobin was measured at 560nm. Diclofenac 
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50µg/mL was used as a reference standard. The percentage of membrane stabilization activity 
of the compounds were determined by the formula  
% membrane stabilization  =    [Acontrol- (A test - A product control) ] / Acontrol x 100 
Acontrol    - Absorbance in control 
Atest    - Absorbance in test 
Aproduct control   - Absorbance in product control. 
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C. IN-VITRO ANTIDIABETIC ACTIVITY55,56 
                
(i) Evaluation of anti-diabetic activity by Non enzymatic glycosylation of                        
haemoglobin assay: 
     
Materials and Method 
               
Equipment: 
 
  UV Spectrophotometer. 
 
Reagents: 
                    
 2% Glucose 
                               
  0.06% Haemoglobin 
 
  0.02% Gentomycin 
 
  0.01M Phosphate buffer(pH 7.4) 
 
Drugs:    
 
 Standard drugs  : Different concentration of Alpha-tocopherol.  
                            
 Test drug          : Different concentration of Compounds K1-K10. 
 
 
Procedure: 
 Anti-diabetic activity was performed by the following  procedure of KINNARI 
N.MISTRY et al. The anti-diabetic activity of the compounds was evaluated by the non-
enzymatic glycosylation of haemoglobin method. The assay is based on the inhibition of 
haemoglobin glycosylation by the compounds and subsequent formation  of glucose 
haemoglobin complex.1Ml of compounds (100µg/ml, 200µg/ml, 300µg/ml)  was combined 
with 1ml  of  2% glucose solution then add 1ml of  0.06% haemoglobin  and 0.02%  
Gentamycin( The solutions were prepared in 0.01M phosphate buffer(pH7.4) In case blank 
1ml of phosphate buffer used in place of compounds. Mixture was incubated in dark place at 
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room temperature for 72 hrs. the degree of  glycosylation of  haemoglobin was measured at 
520nm. Alpha-Tocopherol was  used as a standard drug for assay.                  
       The percentage glycosylation of Haemoglobin was calculated by using following 
formula     =  Test – Control / Test x 100 
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(ii) Evaluation of Anti-diabetic activity by Alpha amylase enzyme inhibition 
Assay. 
Materials and Methods:  
Equipment: 
UV-Visible spectroscopy. 
 Incubator.  
 
Reagents:  
 α-amylase enzyme.  
0.1mM Acetate Buffer (7.2PH) 
Potato Starch(1%w/v) 
Iodine-Iodide indicator. 
 
Drugs: 
             Standard drug     -   Different concentration of Acarbose 
             Test Drug             -   Different concentration of compounds K1-K10 
 
Procedure:   
                    Anti-diabetic activity was performed by the procedure of  KINNARI 
N.MISTRY. The Anti-Diabetic activity of the compounds was evaluated by the α-amylase 
inhibition assay. The assay is based on the inhibition of α-amylase enzyme (α-amylase 
hydrolyses alpha-bonds of large alpha linked polysaccharide such as glycogen and starch to 
yield glucose and maltose. 1ml of compounds (100μg/ml, 200μg/ml, 300μg/ml) was 
combined with 1ml of potato starch(1%w/v) soution, 1ml of α-amylase enzyme(1%w/v) and 
2ml of acetate buffer 0.1mM (Note:Potato starch solution, α-amylase enzyme solution and 
drug solution was prepared in acetate buffer). In case blank 1ml of Acetate buffer was used in 
the place of compounds.  The above mixture was incubate for 1hr. Then 0.1ml iodine-iodide 
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indicator was added in the mixture (635mg iodine and 1gm potassium iodide in 250ml 
distilled water).  Absorbance was measured at 565nm in UV-Visible spectrosocopy. The anti-
diabetic activity of each synthesized  compounds was compared with the % inhibition of 
standard. 
                      The % Inhibition was calculated by using following formula 
                           % Inhibition     = Test - Control / Test x 100 
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(iii) Evaluation of Anti-diabetic activity by α-Glucosidase enzyme inhibition assay 
Materials and Methods: 
Equipment: 
UV-Visible spectrophotometer. 
Reagents: 
              2% w/v Sucrose 
             α-Glucosidase 
             0.2M Tris Buffer(PH8) 
Drug: 
Standard drug           -   Different concentration of  Acarbose. 
Test Drug                 -    Different  concentration of compound K1-K10. 
Procedure: 
             Anti-diabetic activity was performed by the following procedure of 
R.MANIKANDAN et al. The anti-diabetic activity of the compound was evaluated by the α-
glucosidase inhibition assay. The assay is based on the inhibition of α-Glucosidase enzyme 
and inhibit the formation of glucose level in blood. 1ml of compounds (100μg/ml, 200μg/ml, 
300μg/ml) was combined with 1ml of 2%w/v of sucrose solution then add 1ml of 0.2M Tris 
Buffer PH8. The reaction was initiated by adding 1ml of α-Glucosidase enzyme (1U/ml) to it 
followed by incubation for 40 minutes at 35◦C.Then the reaction was terminated by the 
addition of 2ml of 6N Hcl. Then the intensity of the colour was measured at 540nm. The % 
inhibition was calculated by using following formula         
                             % inhibition  =    Control  - Test / Control x100 
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D. IN-VITRO ANTI-TUBERCULOSIS ACTIVITY53,52 
Evaluation of Anti-tuberculosis activity by Mycobacterium tuberculosis susceptibility 
testing. 
Materials: 
                  Versa trek Myco bottle 
                  Mycogrowth Supplement 
                 Sterile distilled water 
                 Tubes with sterile saline 
                 Tuberculin Syringes 
                 Sterile Filter packs. 
Drugs: 
                 Standard drugs   :        Different concentration of Isoniazid 
                 Test drug           :       Different concentration of compound K1, K2, K3, K8. 
Procedure: 
A. Preparation of drug solution (INH and Synthesized compounds) 
1. Add 25ml of sterile distilled water to each of three drug containing 
(75μg) bottles. Swirl to dissolve the contents. Dilute 1:1 with sterile 
distilled water. 
2. Remove 5ml of the rehydrated drug solution and add to a sterile tube 
containing 15ml of sterile distilled water. Label as above(0.1μg/ml). 
B. Preparartion of Inoculum: 
1. Prepare a suspension of the test organism in tubes containing sterile 
saline and glass beads. 
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2. Vortex well and allow the larger particles to settle for at least 30 
minutes. Remove the upper half of suspension to a sterile tube and adjust 
with sterile saline , to a turbidity matching that of a 1.0 MCFarland 
Standard. 
3. Dilute 1:10 with sterile saline. This suspension serves as the inoculum. 
C. Inoculation of bottles: 
1. Add 0.5 ml of inoculum to each of the drug containing and control 
bottles. 
2. Inoculate a 7H11 agar plate with  a few drops of the inoculum to serve 
as a purity check. 
3. Invert the bottle several times to mix the contents. 
4. Each bottle place onto a connector.  
D. Bottle Accessioning and Reading: 
1. Accession each bottle into the ESP Myco system . 
2. Record the time to the nearest 9 days. 
3. Within 9 days drug and  control bottle signals positive, remove from the 
system and confirm the presence of Mycbacterium tuberculosis by 
performing a kinyoun stain. 
 
  
 
RESULT   AND  DISCUSSION 
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5.RESULTS AND DISCUSSION 
5.1  Characterization of synthesized compounds 
Table-2:  List of synthesied compounds with IUPAC Name 
Compound                      Structure with IUPAC Name 
 
 
 
            
            K1 
 
        
N
N
Cl
5-(4-chlorophenyl)-1,3-diphenyl-4,5-dihydro-1H-pyrazole  
 
 
 
 
           K2 
 
                
N
N
OCH3
OCH3
OCH3
5(3,4,5,trimethoxyphenyl)-1,3-diphenyl-4,5-dihydro-1H-pyrazole
 
 
 
 
 
           K3 
 
      
N
N
N
CH3
CH3
4-(1,3-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)-N,N-dimethylaniline  
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Compound                   Structure with IUPAC Name 
 
 
 
 
 
         K4 
 
N
N
OCH3
5-(4-methoxyphenyl)-1,3-diphenyl-4,5-dihydro-1H-pyrazole  
 
 
 
 
        K5 
    
             
N
N
1,3,5-triphenyl-4,5-dihydro-1H-pyrazole  
 
 
 
 
 
       K6 
 
   
          
NH NH
O
Cl
6-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one  
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Compound Structure with IUPAC Name 
 
 
 
 
 
 
          K7 
 
 
 
 
 
 
NH NH
O
OCH3
OCH3
OCH3
4-phenyl-6-(3,4,5-trimethoxyphenyl)-3,4-dihydropyrimidin-2(1H)-one  
 
 
 
 
 
 
 
 
 
 
 
         K8 
 
 
NH NH
O
N
CH3
CH3
6-[4-(dimethylamino)phenyl]-4-phenyl-3,4-dihydropyrimidin-2(1H)-one  
 
 
          
 
 
 
 
        K9 
 
 
 
           
NH NH
O
OCH3
6-(4-methoxyphenyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one  
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Compound                    Structure with IUPAC Name 
 
 
 
 
 
 
          K10 
 
 
 
 
                          
NH NH
O
4,6-diphenyl-3,4-dihydropyrimidin-2(1H)-one  
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Physical Data of Synthesized compounds 
Table -3 
 
   Compound    Molecuar         
formula 
  Nature    Soluble in     % Yield 
 
           
         K1 
 
C21H17ClN2 
 
   Brown solid 
      
     DMSO 
      
      74 
 
         K2 
 
C24H24N2O3 
 
   Brown solid 
 
      DMSO 
 
      
      76 
         
        K3 
 
  C23H23N3 
 
  Brown solid 
 
     DMSO 
 
 
  
       72 
     
        K4 
 
 C22H20N2O 
 
  Brown solid 
 
       DMSO 
 
  
      69 
       
        K5 
 
  C21H18N2 
 
  Brown solid 
 
       DMSO 
 
 
      65 
    
       K6 
 
C16H13ClN2O 
 
  Yellow solid 
 
     DMSO 
 
 
 
     73 
       
       K7 
 
C19H20N2O4 
 
  Yellow solid 
 
      DMSO 
 
 
    74 
    
      K8 
 
C18H19N30 
 
 Orange solid 
 
     DMSO 
 
    68 
 
      K9 
 
C17H16N202 
 
  Yellow solid 
  
    DMSO 
 
    65 
   
     K10 
 
C16H14N20 
 
  Yellow solid 
    
     DMSO 
 
   62 
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                                 Physical data of synthesized compounds 
Table-4 
 
 
Compound 
 
 
Melting point (◦C) 
 
Rf Value 
 
K1 
 
173 0.45 
 
K2 
 
175 0.47 
 
K3 
 
172 0.48 
 
K4 
 
179 0.43 
 
K5 
 
171 0.39 
 
K6 
123 0.62 
 
 
 
K7 
127 0.65 
 
 
 
K8 
129 0.68 
 
K9 
126 0.7 
 
K10 
120 0.61 
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                                   Elemental composition of compounds 
Table-5 
 
 
         Compound 
 
          Elemental Composition in Percentage (%) 
C H Cl N O 
K1  
84.53 
 
 
6.08 
 
10.65 
 
8.42 
 
         - 
K2  
74.78 
 
 
6.23 
 
       - 
 
7.21 
 
12.36 
K3  
80.90 
 
 
6.79 
 
       - 
 
12.31 
 
        - 
K4  
80.46 
 
 
6.14 
 
      - 
 
8.53 
 
4.87 
K5  
84.53 
 
 
6.08 
 
       - 
 
9.39 
 
       - 
K6  
67.49 
 
 
4.60 
 
12.45 
 
9.84 
 
5.62 
K7  
67.05 
 
5.92 
 
      - 
 
8.23 
 
 
18.80 
K8  
73.69 
 
6.53 
 
      - 
 
14.32 
 
 
5.45 
K9  
72.84 
 
5.75 
 
     - 
 
9.99 
 
 
11.42 
K10  
76.78 
 
5.64 
 
     - 
 
11.19 
 
 
6.39 
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           5.2 LIPINSKI PROPERTIES OF SYNTHESIZED COMPOUNDS 
Table-6 
 
Compound Molecular 
Weight 
LogP H-bond 
donor 
H-bond 
acceptor 
Molar 
refractivity 
Number 
criteria 
met 
K1          
332.82 
            
6.174 
                   
0 
                    
2 
               
100.85 
 4 
 
K2          
388.45 
            
5.183 
                   
0 
                    
5 
               
115.50 
 
4 
K3          
341.44 
            
6.183 
                   
0 
                    
3 
               
110.17 
 
4 
K4          
328.40 
              
5.88 
                   
0 
                    
3 
                
102.40 
 
4 
K5          
298.38 
              
4.83 
                   
0 
                    
4 
            
98.52 
 
ALL 
K6          
284.74 
               
3.728 
                   
2 
                    
3 
                 
81.13 
 
ALL 
K7             
340.37 
               
2.737 
                   
2 
                    
6 
               
95.7 
 
ALL 
K8             
293.36 
                
3.737 
                   
2 
                    
4 
                  
91.23 
 
ALL 
K9               
280.32 
                  
3.44 
                   
2 
                    
4 
               
83.46 
 
ALL 
K10          
250.29 
                 
3.106 
                   
2 
                    
3 
               
76.91 
 
ALL 
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                                       5.3  SPECTRAL ANALYSIS 
                                       IR Data of Synthesized compounds 
        Table-7 
       Compound K1-K5 
COMPOUNDS VIBRATION MODE 
 
 
OBSERVED FREQUENCY 
 
K1 
C=C Streching 
C=N Streching 
C-N Streching 
Ar -  Cl Streching 
Ar-C-H Streching 
1494.83 
1587.42 
1033.85 
754.17 
3061.03 
K2 C=C Streching  
C=N Streching  
C-N Streching 
C-O-C Streching 
Ar-C-H Streching 
1579 
1548 
1182 
1070 
3049 
K3 C=C Streching  
C=N Streching 
C-N Streching 
Ar-N-CH3 Streching 
Ar-C-H Streching 
1548 
1579 
1112 
1357 
3049 
K4 C=C Streching 
C=N Streching 
C-N Streching 
Ar-OH Streching 
Ar-C-H Streching 
1492 
1500 
1172 
1388 
3059 
K5 C=C Streching 
C=N Streching 
C-N Streching 
Ar-C-H Streching 
1492 
1589 
1168 
3059 
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         Compound K6-K10 
 
COMPOUNDS VIBRATION MODE 
 
 
FREQUENCY Cm-1 
K6 C=C Streching 
C-N Streching 
Ar-C-H Streching 
Ar-Cl Streching 
C=O Streching 
1480 
1219.01 
3059 
688.59 
1591 
 
K7 C=C Streching 
C-N Streching 
Ar-C-H Streching 
C-O-C Streching  
C=O Streching 
1581.63 
1178.51 
2995.45 
1033.85 
1591.63 
K8 C=C Streching 
C-N Streching 
Ar-C-H Streching 
N-CH3 Streching 
C=O Streching 
1581.63 
1020.34 
3091 
1346.31 
1581.63 
K9 
 
C=C Strecching 
C-N Sterching 
Ar-C-H Streching 
Ar-OH Streching 
C=O Streching 
1573.91 
1213.23 
3039.85 
1301.95 
1600.92 
K10 C=C Streching 
C-N Streching 
Ar-C-H Streching 
C=O Streching 
1579.7 
1219.01 
3061.03 
1598.99 
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COMPOUND K1 
 
COMPOUND K2 
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COMPOUND K3 
 
COMPOUND  K4 
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COMPOUND K5 
 
COMPOUND  K6
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COMPOUND K7 
 
COMPOUND K8 
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COMPOUND K9 
 
 
COMPOUND K10
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1HNMR Spectral data 
Table-8  
Compounds A1-A5 
 
 
            Compound 
 
 
      Chemical Shift Value            Proton nature 
          
              K1 
          7.2 
          6.8 
          2.6    
m, 10H, Ar-H, 
s, 4H, Ar-H 
s, 1H, CH 
  
 
K2 
          7.8 
          6.9  
          2.6 
          3.5 
S,10H, Ar-H 
S, 4H, Ar-H 
S, 1H, CH 
d, 9H, OCH3 
 
 
K3 
          7.8 
          6.9 
          6.7 
          2.3 
10H, Ar-H 
4H, Ar-H 
3H, N-CH3 
s, 1H, CH 
 
 
K4 
          7.8 
          6.2 
          3.5 
          2.4   
s, 10H, Ar-H 
s, 4H, Ar-H 
s, 3H, OCH3 
d, 1H, CH 
 
 
K5 
          7.8 
          7.5 
          2.3 
 
s, 10H, Ar-H 
s, 4H, Ar-H 
s, 1H, CH 
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Compounds K6-K7 
  Compounds 
 
 
Chemical Shift value Proton nature 
         
 K6  
 
 
         7.3 
         6.9 
         2.7      
s, 5H, Ar-H 
s, 4H, Ar-H 
s, 2H, 2NH 
 
             K7 
         7.3 
         6.8 
         2.5 
         3.5 
s, 5H, Ar-H 
s, 4H, Ar-H 
s, 2H, 2NH 
s, 9H, OCH3 
 
K8 
         7.8 
         7.3 
         2.5 
         3.5 
d, 5H, Ar-H 
s, 4H, Ar-H 
s, 2H, 2NH 
s, 3H, N-CH3 
 
             K9 
         7.5 
         7.2 
         2.5 
         3.5 
s, 5H, Ar-H 
s, 4H, Ar-H 
s, 2H, 2NH 
s, 3H, OCH3 
 
           K10  
         7.8 
         7.3 
         2.7 
 
s, 5H, Ar-H 
s, 4H, Ar-H 
s, 2H, 2NH 
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COMPOUND K1 
         
         
           Current Data Parameters 
       NAME   Feb08−2014 
       EXPNO   11 
               PROCNO  1 
               F2 − Acquisition Parameters
       Date_   20140208 
       Time   22.10 
       INSTRUM  spect 
               PROBHD  5 mm PABBO BB−
       PULPROG zg30 
       TD   32768 
       SOLVENT  DMSO 
       NS   32 
               DS   2 
       SWH   10330.578 Hz 
               FIDRES   0.315264 Hz 
               AQ  1.5860212 sec 
               RG   203 
       DW   48.400 usec 
       DE   6.50 usec 
               TE   300.1 K 
       D1 1.00000000 sec
               TD0   1 
               ======== CHANNEL f1 ========
               NUC1   1H 
               P1   10.65 usec 
       PL1   0.00 dB 
       PL1W   23.53637505 W
               SFO1  500.1330885 MHz
               F2 − Processing parameters
               SI   32768 
       SF 500.1300035 MHz
       WDW   EM 
       SSB   0 
       LB   0.30 Hz 
       GB   0 
               PC   1.00 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
 1. 00
 
   
0.
94
0.
99
0.
88
1.
12
1.3
41
.0
60
.9
80
.91
 
           
  
 
COMPOUND K2 
                  
           Current Data Parameters
      NAME   Feb08−2014
               EXPNO   11 
               PROCNO  1 
               F2 − Acquisition Parameters
      Date_   20140208
               Time   22.10 
               INSTRUM  spect
               PROBHD  5 mm PABBO BB−
               PULPROG zg30
               TD   32768 
      SOLVENT  DMSO
      NS   32 
      DS   2 
               SWH   10330.578 Hz
               FIDRES   0.315264 Hz
               AQ  1.5860212 sec
               RG   203 
      DW   48.400 usec
      DE   6.50 usec
               TE   300.1 K 
      D1 1.00000000 sec
               TD0   1 
      ======== CHANNEL f1 ========
               NUC1   1H 
      P1   10.65 usec
      PL1   0.00 dB 
               PL1W   23.53637505 W
               SFO1  500.1330885 MHz
               F2 − Processing parameters
      SI   32768 
               SF 500.1300035 MHz
               WDW   EM 
               SSB   0 
      LB   0.30 Hz 
      GB   0 
               PC   1.00 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
 1. 00
 
   
0.9
40
.9
90
.88
1.1
21
.34
1.
06
0.9
80
.91
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COMPOUND K3 
         
           Current Data Parameters
              NAME   Feb08−2014
              EXPNO   24 
              PROCNO  1 
              F2 − Acquisition Parameters
              Date_   20140208 
              Time   4.40 
              INSTRUM  spect 
              PROBHD  5 mm PABBO BB−
              PULPROG zg30
              TD   32768 
              SOLVENT  DMSO
              NS   32 
              DS   2 
              SWH   10330.578 Hz
              FIDRES   0.315264 Hz
              AQ  1.5860212 sec
              RG   203 
              DW   48.400 usec
              DE   6.50 usec
              TE   299.3 K 
              D1 1.00000000 sec
              TD0   1 
       ======== CHANNEL f1 ========
              NUC1   1H 
              P1   10.65 usec
              PL1   0.00 dB 
              PL1W   23.53637505 W
              SFO1  500.1330885 MHz
              F2 − Processing parameters
              SI   32768 
              SF 500.1300043 MHz
              WDW   EM 
              SSB   0 
              LB   0.30 Hz 
              GB   0 
       PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
    1.
00
 
   1.
85
 
 9.
80
 
2.
1
0       
 
COMPOUND K4 
         
           Current Data Parameters 
              NAME   Feb08−2014 
              EXPNO   15 
              PROCNO  1 
              F2 − Acquisition Parameters
              Date_   20140208 
              Time   22.23 
        INSTRUM  spect 
              PROBHD  5 mm PABBO BB−
              PULPROG zg30 
              TD   32768 
              SOLVENT  DMSO 
              NS   32 
              DS   2 
              SWH   10330.578 Hz 
        FIDRES   0.315264 Hz 
              AQ  1.5860212 sec 
              RG   203 
        DW   48.400 usec 
              DE   6.50 usec 
              TE   300.0 K 
              D1 1.00000000 sec 
              TD0   1 
              ======== CHANNEL f1 ========
              NUC1   1H 
              P1   10.65 usec 
              PL1   0.00 dB 
              PL1W   23.53637505 W 
              SFO1  500.1330885 MHz
              F2 − Processing parameters
              SI   32768 
              SF 500.1300000 MHz 
              WDW   EM 
              SSB   0 
              LB   0.30 Hz 
        GB   0 
              PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
   3.
02
 
 1.00
2.1
6 
 2.
20
 
   6.
1
6  2.
0
4       
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 COMPOUND K5 
             Current Data Parameters 
                NAME   Feb08−2014 
        EXPNO   22 
                PROCNO  1 
                F2 − Acquisition Parameters 
                Date_   20140208 
        Time   4.33 
                INSTRUM  spect 
                PROBHD  5 mm PABBO BB− 
        PULPROG zg30 
                TD   32768 
        SOLVENT  DMSO 
                NS   32 
                DS   2 
        SWH   10330.578 Hz 
                FIDRES   0.315264 Hz 
        AQ  1.5860212 sec 
                RG   203 
        DW   48.400 usec 
                DE   6.50 usec 
                TE   299.3 K 
                D1 1.00000000 sec 
                TD0   1 
        ======== CHANNEL f1 ======== 
                NUC1   1H 
                P1   10.65 usec 
        PL1   0.00 dB 
                PL1W   23.53637505 W 
                SFO1  500.1330885 MHz 
                F2 − Processing parameters 
                SI   32768 
                SF 500.1300000 MHz 
        WDW   EM 
                SSB   0 
                LB   0.30 Hz 
                GB   0 
                PC   1.00 
13 12 11 10 9 8  7 6 5 4 3  2 1 0 ppm    
    7.
81
 1.
00
 
1.
17
 
1.
21
 
2.
74
 
  0.
61
 
1.
60
 
15
.9
9 
      
  
 
COMPOUND K6 
      
            Current Data Parameters 
               NAME   Feb09−2014 
               EXPNO   8 
               PROCNO  1 
               F2 − Acquisition Parameters 
               Date_   20140209 
               Time   22.00 
               INSTRUM  spect 
               PROBHD  5 mm PABBO BB− 
       PULPROG zg30 
       TD   32768 
               SOLVENT  DMSO 
               NS   32 
               DS   2 
               SWH   10330.578 Hz 
               FIDRES   0.315264 Hz 
               AQ  1.5860212 sec 
               RG   203 
               DW   48.400 usec 
               DE   6.50 usec 
               TE   300.1 K 
               D1 1.00000000 sec 
               TD0   1 
               ======== CHANNEL f1 ======== 
               NUC1   1H 
               P1   10.65 usec 
               PL1   0.00 dB 
       PL1W   23.53637505 W 
               SFO1  500.1330885 MHz 
               F2 − Processing parameters 
               SI   32768 
               SF 500.1300041 MHz 
               WDW   EM 
               SSB   0 
               LB   0.30 Hz 
               GB   0 
       PC   1.00 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
0.
66
 
 1.
07
 
   
1.0
01
.03
0.9
61
.05
1.0
01
.03
1.0
0 
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COMPOUND K7 
           
           Current Data Parameters 
              NAME   Feb09−2014 
              EXPNO   6 
              PROCNO  1 
              F2 − Acquisition Parameters 
              Date_   20140209 
              Time   21.53 
              INSTRUM  spect 
              PROBHD  5 mm PABBO BB− 
              PULPROG zg30 
              TD   32768 
              SOLVENT  DMSO 
              NS   32 
              DS   2 
              SWH   10330.578 Hz 
              FIDRES   0.315264 Hz 
              AQ  1.5860212 sec 
              RG   203 
              DW   48.400 usec 
              DE   6.50 usec 
              TE   300.1 K 
              D1 1.00000000 sec 
              TD0   1 
              ======== CHANNEL f1 ========
              NUC1   1H 
              P1   10.65 usec 
              PL1   0.00 dB 
              PL1W   23.53637505 W 
              SFO1  500.1330885 MHz 
              F2 − Processing parameters 
              SI   32768 
              SF 500.1300000 MHz 
              WDW   EM 
              SSB   0 
              LB   0.30 Hz 
              GB   0 
              PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
 1.
07
 
  
0.1
21
.02
0.1
31
.05
0.9
41
.14
1.0
11
.04
1.0
0 
   0. 85
  0.
32
 
     
  
 
COMPOUND K8                                                                
           Current Data Parameters 
               NAME  Feb09−2014 
               EXPNO  10 
               PROCNO 1 
               F2 − Acquisition Parameters 
               Date_  20140209 
               Time  22.06 
               INSTRUM spect 
               PROBHD 5 mm PABBO BB− 
               PULPROG zg30 
               TD  32768 
         SOLVENT DMSO 
               NS  32 
               DS  2 
               SWH  10330.578 Hz 
               FIDRES  0.315264 Hz 
               AQ  1.5860212 sec 
               RG  203 
               DW  48.400 usec 
               DE  6.50 usec 
               TE  300.1 K 
               D1 1.00000000 sec 
               TD0  1 
               ======== CHANNEL f1 ======== 
               NUC1  1H 
               P1  10.65 usec 
               PL1  0.00 dB 
               PL1W  23.53637505 W 
               SFO1  500.1330885 MHz 
               F2 − Processing parameters 
         SI 32768 
         SF 500.1300042 MHz 
               WDW  EM 
               SSB  0 
               LB  0.30 Hz 
               GB  0 
         PC 1.00 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm   
0.
56
 
 1.
01
 
  1.
00
 
0.9
92
.10
4.1
71
.03
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COMPOUND K9 
          Current Data Parameters 
              NAME   Feb09−2014 
              EXPNO   14 
              PROCNO  1 
              F2 − Acquisition Parameters 
              Date_   20140209 
              Time   22.20 
              INSTRUM  spect 
              PROBHD  5 mm PABBO BB− 
              PULPROG zg30 
       TD   32768 
              SOLVENT  DMSO 
              NS   32 
              DS   2 
              SWH   10330.578 Hz 
              FIDRES   0.315264 Hz 
              AQ  1.5860212 sec 
              RG   203 
              DW   48.400 usec 
              DE   6.50 usec 
              TE   300.1 K 
       D1 1.00000000 sec 
       TD0   1 
              ======== CHANNEL f1 ========
              NUC1   1H 
              P1   10.65 usec 
       PL1   0.00 dB 
              PL1W   23.53637505 W 
              SFO1  500.1330885 MHz 
              F2 − Processing parameters 
              SI   32768 
       SF 500.1300043 MHz 
              WDW   EM 
       SSB   0 
              LB   0.30 Hz 
              GB   0 
              PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
  1.
00
 
 1.
0
2 0.
41
 
9.4
30
.96
 
           
  
 
 
COMPOUND K10
           Current Data Parameters 
              NAME  Feb09−2013 
              EXPNO  21 
              PROCNO 1 
              F2 − Acquisition Parameters 
              Date_  20140209 
              Time  4.30 
              INSTRUM spect 
              PROBHD 5 mm PABBO BB− 
              PULPROG zg30 
              TD  32768 
              SOLVENT DMSO 
              NS  32 
              DS  2 
              SWH  10330.578 Hz 
              FIDRES  0.315264 Hz 
              AQ  1.5860212 sec 
              RG  203 
              DW  48.400 usec 
              DE  6.50 usec 
              TE  299.5 K 
              D1 1.00000000 sec 
              TD0  1 
              ======== CHANNEL f1 ======== 
              NUC1  1H 
              P1  10.65 usec 
              PL1  0.00 dB 
              PL1W  23.53637505 W 
              SFO1  500.1330885 MHz 
              F2 − Processing parameters 
              SI  32768 
              SF 500.1300000 MHz 
              WDW  EM 
              SSB  0 
              LB  0.30 Hz 
              GB  0 
              PC  1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm   
 0. 9 0    1.
00
 
2.2
31
.15
 
  7.
21
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                               MASS Spectra of synthesized compounds 
Table-9:  
 
 
                  COMPOUND 
            
 
   MOLECULAR ION PEAK 
 
                    K1 
           332.82  
 
                    K2 
           388.45     
 
                    K3 
           341.44 
 
                    K4 
           328.40 
 
                    K5 
           298.38 
 
 K6 
           284.74 
 
                    K7 
           340.37 
 
 K8 
           293.36 
 
  K9 
          280.32 
 
                     K10 
           250.29                                   
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COMPOUND K1 
 
 
 
COMPOUND K2 
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COMPOUND K3 
 
 
 
 
COMPOUND K4 
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COMPOUND K5 
 
 
 
 
COMPOUND K6 
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COMPOUND K7 
 
 
 
 
COMPOUND K8 
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COMPOUND K9 
 
 
 
 
COMPOUND K10 
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5.4 Results of Biological activity 
A)  In-vitro Anti-oxidant activity 
    
  Table-10: Absorbance of synthesized compounds compared with standard                        
anti-oxidant activity. 
 
 
 
    Compounds 
               Absorbance of different  concentration 
 
100μg/ml 
 
200μg/ml 300μg/ml 
K1 1.62±0.02 1.72±0.03 
 
1.89±0.02 
K2 1.34±0.06 1.63±0.06 
 
1.82±0.09 
 
K3 1.63±0.07 1.77±0.04 
 
2.02±0.07 
K4 1.34±0.03 1.45±0.04 
 
1.62±0.04 
K5 1.37±0.04 1.43±0.04 
 
1.53±0.03 
K6 1.53±0.03 1.62±0.03 
 
1.88±0.02 
K7 1.48±0.04 1.69±0.02 1.81±0.01 
K8 1.5±0.03 
 
1.8±0.03 2.01±0.05 
K9 1.49±0.06 
 
1.53±0.06 
 
1.59±0.09 
 
K10 1.16±0.05 1.35±0.06 1.55±0.06 
Standard 
(Ascorbic acid) 
 
1.68±0.04 
 
1.87±0.06 
 
2.15±0.05 
 
                             
                                             
 
 
 
 0
0.5
1
1.5
2
2.5
K6 K7 K8 K9 K10 STD
A
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O
RB
A
N
CE
COMPOUNDS K6‐K10
ABSORBANCE OF SYNTHESIZED COMPOUNDS K6‐K10
100µg/ml
200µg/ml
300µg/ml
 
 
0
0.5
1
1.5
2
2.5
K1 K2 K3 K4 K5 STD
A
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O
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A
N
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COMPOUNDS K1‐K5
ABSORBANCE OF SYNTHESIZED COMPOUNDS K1‐K5
100µg/ml
200µg/ml
300µg/ml
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A) MEMBRANE STABILIZATION ASSAY 
          
             Table 11: Anti-inflammatory acitivity of synthesized compounds K1-K10 
 
 
 
COMPOUNDS 
            PERCENTAGE OF  ACTIVITY 
 
 
200μg/ml 
 
400μg/ml 
 
600μg/ml 
K1  
67.41±0.14 
 
73.29±0.12 
 
76.16±0.05 
K2  
63.69±0.08 
 
67.71±0.09 
 
72.66±0.08 
K3  
78.97±0.08 
 
82.97±0.08 
 
86.10±0.09 
K4  
61.44±0.05 
 
65.13±0.07 
 
69.54±0.06 
K5  
58.77±0.06 
 
64.72±0.04 
 
68.17±0.08 
K6  
70.09±0.08 
 
74.41±0.09 
 
78.20±0.09 
K7  
 
 
64.10±0.09 
 
68.22±0.06 
 
73.19±0.07 
K8 
 
 
76.25±0.02 
 
80.19±0.06 
 
84.22±0.08 
K9 
 
 
60.34±0.09 
 
65.23±0.05 
 
69.11±0.1 
K10 
 
 
56.96±0.08 
 
62.27±0.09 
 
66.37±0.08 
STD 
(Diclofenac) 
                           
78.74±0.06 
                          
84.21±0.05 
                       
88.43±0.07 
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C.IN-VITRO ANTI-DIABETIC ACTIVITY 
               Table-12: Non-Enzymatic Glycosylation of Haemoglobin Method  
 
COMPOUND
S 
% INHIBITION OF HAEMOGLOBIN GLYCOSYLATION 
 
50μg/ml 100μg/ml 150μg/ml 
K1     53.42 
 
     67.07   73.58 
K2    52.61 
 
     66.32   72.92 
K3    47.58 
 
    63.11   71.50 
K4    43.79 
 
    61.00   69.58 
K5    38.95 
 
    58.52   67.26 
K6    51.05 
 
    65.68   73.28 
K7    49.84 
 
     64.87   71.94 
K8    45.11 
 
    62.61   70.41 
K9    40.29 
 
    60.04   68.53 
K10    34.27 
 
    58.62   67.00 
STD 
(Tocopherol) 
   55.46 
 
    67.85   74.04 
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Table-13: Alpha amylase enzyme inhibition assay. 
 
COMPOUNDS         % INHIBITION OF ALPHA AMYLASE ENZYME  
50μg/ml 100μg/ml 150μg/ml 
K1       61.22 
 
         76.71          82.4 
K2      55.60 
 
        74.25        78.31 
K3      45.00 
 
        70.01        74.46 
K4      41.71 
 
        68.7          72 
K5      44.20 
 
       69.52        73.00 
K6      50.03 
 
       73.13        76.42 
K7      46.01 
 
       71.03        75.45 
K8      44.05 
 
       69.52        73.04 
K9     34.01 
 
       65.06        69.00 
K10    18.12 
 
     45.13      61.18 
STD 
(Acarbose) 
   64.17 
 
     77.90      82.97 
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 Table-14:  Alpha Glucosidase enzyme Inhibition Assay  
 
 
 
COMPOUNDS 
 
 
% INHIBITION OF ALPHA GLUCOSIDSE  ENZYME 
50μg/ml 100μg/ml 150μg/ml 
K1     42.76 
 
    60.13     81.60 
K2     41.36 
 
    58.91     80.57 
K3     37.34 
 
    55.46     75.25 
K4     36.32 
 
    54.34     72.54 
K5     34.36 
 
    51.44     70.68 
K6     78.99 
 
    40.80     58.91 
K7    38.74 
 
    56.95     77.31 
K8                36.88 
 
    54.15     73.33 
K9   35.85 
 
  53.12    71.80 
K10   32.02 
 
  50.23    69.65 
STD (Acarbose)   44.07 
 
  61.81    82.63 
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                                                   5.5 DISCUSSION 
  The molecular design of all synthesized compounds were done by using different 
software such as Chemdoole, Chemsketch and Molinspiration. 
  The lipinski rule was predicted for all synthesized compound using CHEMDOODLE. 
      It shows no violation in basic properties .The results were shown in Table.No: 6 
 The I.U.P.A.C name were predicted by using chemsketch. The results were shown in 
Table.No:2 
 The pecentage yield, Mocular Formula, solubility and appearance of the compounds 
were pridicted  and shown in Table.No;3 
 The purity of the compounds were found out by TLC and Rf value was calculated. The 
results are shown in Table.No:4 
 Melting points of compounds were predicted and shown in Table.No:4 
 Elemental compostion were found and calculated in percentage and results obtained 
were shown in Table. No:5 
 The Characterisation of synthesized compounds were confirmed by IR spectra,NMR 
spectra and Mass spectra. 
 IRspectra interpret value shown in Table.No:7 
 NMR specctra interpret value shown in Table.No:8 
 Mass spectra results are shown in Table.No.9 
 All synthesized compounds were evaluated for ant-oxidant, anti-diabatic acitivity, anti-
inflammatory and anti-tuberculosis activity. 
 Anti-Oxidant activity of all synthesized compounds were evaluated and results were 
shown in Table.No:10 
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 In Anti-diabetic evaluation Non-enzymatic Haemoglobin glycosylation assay results 
were shown in Table.No:12 
 In  Anti-diabetic evluation alpha amylase enzyme inhibition assay results were shown in 
Table.No:13 
 In Anti-diabetic evaluation alpha glucosidase enzyme inhiition assay results were shown 
in Table.No:14 
 Anti-inflammatory activty of all synthesized compounds results were shown in 
Table.No:11 
 Anti-tuberculosis activity of synthesized compounds results were shown in Table.No:15 
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6. CONCLUSION 
The  molecules were designed by the software tools and the lead molecules of 
chalcone were synthesized by “ CLAISEN-SCHMIDT REACTION” followed by phenyl 
hydrazine and urea treatment forms N-phenylpyrazoline and 3,4-dihydropyrimidine 
respectively. The formation of molecules was confirmed by TLC.  
The structure of synthesized compounds were confirmed by FT-IR, 1HNMR, MASS 
Spectroscopy. 
The IR data’s showed relavant  peaks for C=C, C=N, C=O groups. The  1HNMR also 
showed relavant proton peaks for all synthesized compounds. The MASS spectrum confirm 
the molecular ion peak of all synthesized compounds. 
 The In-vitro anti-oxidant property for all the compounds showed positive results. The 
compounds K1, K3 & K6, K8 showed more potent activity. These four compounds shows N-
phenylpyrazoline and 3,4-dihydropyrimidine with P-dimethyl amino benzaldehyde, P-
chlorobenzaldehyde substitution at fifth and sixth position respectively. Hence the 
compounds may be evaluated for Anti-tuberculosis activity. 
 The In-vitro anti-diabetic activity of all the compounds was evaluated and compared 
with standard. The compounds such as K1, K2 & K6, K7 showed more potent activity. Hence 
N-phenylpyrazoline and 3,4-dihydropyrimidine with P-Chloro baenzaldehyde, Trimethoxy 
benzaldehyde substitution at fifth and sixth position respectively showed better activity. 
 The In-vitro anti-inflammatory activity of all the compounds was evaluated and 
compared with standard.  All the compounds showed significant activity. The compounds 
such as K1, K3 & K6, K8 exhibited more potent activity. 
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Based on In-vitro antioxidant activity the compounds K1, K3, K6, K8 were selected 
and evaluated for Anti-tuberculosis activity. The compounds K3 exhibit potent activity 
against Mycobacterium tuberculosis. Hence N-phenylpyrazoline with phenyl substitution at 
third position and P-dimehtyl amino benzaldehyde substitution at fifth position showed better 
activity. 
In Future, the compounds K1, K2, K6, K7 can be studied for In-vivo anti-diabetic 
activity as it exhibited significant In-vivo anti-diabetic activity.  
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